US20050019376A1 - Dosage form containing a confectionery composition - Google Patents

Dosage form containing a confectionery composition Download PDF

Info

Publication number
US20050019376A1
US20050019376A1 US10/476,503 US47650304A US2005019376A1 US 20050019376 A1 US20050019376 A1 US 20050019376A1 US 47650304 A US47650304 A US 47650304A US 2005019376 A1 US2005019376 A1 US 2005019376A1
Authority
US
United States
Prior art keywords
dosage form
angle
active ingredient
polarized light
light transmission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/476,503
Inventor
Gerard McNally
Frank Bunick
Harry Sowden
Gus LaBella
Timothy Gilmor
Der-Yang Lee
Martin Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority to US10/476,503 priority Critical patent/US20050019376A1/en
Priority claimed from PCT/US2002/031115 external-priority patent/WO2003026614A1/en
Assigned to MCNEIL-PPC, INC. reassignment MCNEIL-PPC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THOMAS, MARTIN, LEE, DER-YANG, SOWDEN, HARRY S., BUNICK, FRANK J., LABELLA, GUS B., MCNALLY, GERARD P., GILMOR, TIMOTHY P.
Publication of US20050019376A1 publication Critical patent/US20050019376A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/02Apparatus specially adapted for manufacture or treatment of sweetmeats or confectionery; Accessories therefor
    • A23G3/04Sugar-cookers
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/368Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005Coating of tablets or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B30PRESSES
    • B30BPRESSES IN GENERAL
    • B30B11/00Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/02Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space
    • B30B11/08Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space co-operating with moulds carried by a turntable
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B30PRESSES
    • B30BPRESSES IN GENERAL
    • B30B11/00Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2873Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes

Definitions

  • This invention relates to dosage forms such as pharmaceutical compositions comprising a confectionery composition. More particularly, this invention relates to dosage forms containing at least one active ingredient and a confectionery composition such as fat, amorphous sugar glass, or fondant.
  • Confectionery manufacturing facilities for example, are not commonly designed to allow for the rigorous controls on raw material traceability required by the pharmaceutical industry, or equipped for avoiding cross-contamination while processing multiple drug active ingredients.
  • a high-purity water source, closed air-handling system, and on-site analytical laboratory are critical for any pharmaceutical operation. Installing and validating these systems entails substantial cost and complexity.
  • compositions must have minimal variation in the weight of individual dosage units to achieve a high degree of drug content uniformity. Since many confectionery processes were designed without the need for the high degree of precision and reproducibility required for pharmaceuticals, a high degree of variation is inherent in their design. Typical confectionery rope-forming operations, for example, result in high product weight variation due to entrained air, and variations in rope tensile strength, viscosity, and plasticity with temperature. Conventional confectionery cut and wrap operations result in high product weight variation due to variation in flow and thickness of the rope. Extruded confectionery compositions can vary in piece weight due to changes in flow rate, and pulsations in the center fill pumping operation which lead to variations in center fill content. Additionally high weight variation is inherent in confectionery depositing operations, which do not fill a fixed volume, so piece weight depends on the reproducibility of the metered dose pumping, which is subject to variability in viscosity, due to temperature and material factors.
  • Product aesthetics represent another area of discrepancy between the two industries. For example, typical confectionery depositing operations produce a product which can have high definition on only three sides, but necessarily has a “free-formed” surface on one side. In such products, the degree of surface gloss is higher on the free-formed surface than the molded sides. Pharmaceutical products typically require a uniform and consistent appearance implying a high degree of control in the manufacturing process. It is thus desirable to have a manufacturing process which can provide uniform high definition on all sides of the dosage form.
  • Chocolate-coatings over confectionery cores are typically made by filling a cold mold to solidify the outer layer of chocolate, then pouring out the excess, then injecting with the center fill material, or alternatively by dipping the core material into molten chocolate to form the bottom, then enrobing the remainder of the piece by pouring molten chocolate over the top and sides, then dripping off the excess.
  • Such operations are inherently high in weight variation because the coating level depends upon the viscosity of the chocolate which will vary with raw materials, temperature, humidity, etc. Thus these operations do not lend themselves to pharmaceutical dosage forms.
  • the dosage form of this invention comprises at least one active ingredient and a confectionery composition, the dosage form has at least one face, and the relative standard deviation of the weight of the dosage form is less than 1%, preferably 0.5%.
  • the dosage form comprises at least one active ingredient and a confectionery composition wherein the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • the relative standard deviation of the weight of the dosage form is less than 0.5%.
  • the confectionery composition comprises at least one component selected from the group consisting of fat, amorphous sugar glass and fondant.
  • the confectionery composition does not contain a gelatin based composition.
  • the confectionery composition does not contain a gel based composition.
  • the confectionery composition comprises an amorphous sugar glass component and the dosage form does not have a free formed surface.
  • all the faces of the dosage form have a surface gloss of about 200-300 gloss units.
  • the dosage form has two or more faces, and the difference in surface gloss between any two faces is not more than about 20 gloss units.
  • the difference in surface gloss between any two faces is not more than about 15 gloss units.
  • the difference in surface gloss between any two faces is not more than about 10 gloss units.
  • the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • the dosage form has a mean polarized light transmission between about 0 to 40 grayscale units at the angle of maximum extinction.
  • the confectionery composition comprises an amorphous sugar glass component and the dosage form does not have a free formed surface.
  • the active ingredient is a pharmaceutically active ingredient.
  • the dosage form comprises particles which comprise the active ingredient.
  • the particles have an average particle size of about 50 to about 2000 microns.
  • At least a portion of the particles are coated particles.
  • the dosage form is a unitary object.
  • the dosage form does not contain any seams on its surface.
  • the relative standard deviation of the weight of the dosage form is less than 1.0%.
  • the confectionery composition comprises an amorphous sugar glass component.
  • the dosage form is substantially free of pores having a diameter of 0.5 to 5.0 microns.
  • the dosage form of this invention does not contain a gel-based composition or a gelatin-based composition.
  • the dosage form of this invention comprises an amorphous sugar glass component and the dosage form does not have a free formed surface.
  • all the dosage form faces have a surface gloss of about 200-300 gloss units.
  • the dosage form has two or more faces, and the difference in surface gloss between any two faces is not more than about 20 gloss units, preferably not more than about 15 gloss units, most preferably not more than about 10 gloss units.
  • the dosage form has a mean polarized light transmission between about 0 to 40 grayscale units at the angle of maximum extinction.
  • the active ingredient is a pharmaceutically active ingredient.
  • FIG. 1A depicts a prior art composition and a composition of the present invention viewed under normal polarized light.
  • FIG. 1B depicts a prior art composition and a composition of the present invention viewed under polarized light at 90° filtering to the incident light.
  • FIG. 2A is a photograph of a two-piece hard candy lozenge mold which may be used to prepare the dosage form of this invention.
  • FIG. 2B is a photograph of the mold depicted in FIG. 2A together with a lozenge dosage form which has been removed from the mold.
  • FIG. 3A depicts an apparatus for measuring mean polarized light transmission at the angle of maximum transmission.
  • FIG. 3B depicts an apparatus for measuring mean polarized light transmission at the angle of maximum extinction.
  • FIG. 4A depicts typical photographic images taken at the angle of maximum light transmission comparing hard candies made by methods of the prior art and the dosage form of this invention.
  • FIG. 4B depicts typical photographic images taken at the angle of maximum light extinction comparing hard candies made by methods of the prior art and the dosage form of this invention.
  • FIG. 5 shows the greyscale intensity distribution for a CHLORASEPTIC throat lozenge at both the angle of maximum light transmission and the angle of maximum light extinction.
  • FIG. 6 shows the greyscale intensity distribution for the product of the present invention at both the angle of maximum light transmission and the angle of maximum light extinction.
  • dosage form applies to any solid object, semi-solid, or liquid composition, designed to contain a specific predetermined amount (i.e. dose) of a certain ingredient, for example an active ingredient as defined below.
  • Suitable dosage forms may be pharmaceutical drug delivery systems, including those for oral administration, buccal administration, rectal administration, topical, transdermal, or mucosal delivery, or subcutaneous implants, or other implanted drug delivery systems; or compositions for delivering minerals, vitamins and other nutraceuticals, oral care agents, flavorants, and the like.
  • the dosage forms of the present invention are considered to be solid, however they may contain liquid or semi-solid components.
  • the dosage form is an orally administered system for delivering a pharmaceutical active ingredient to the gastro-intestinal tract of a human.
  • the dosage form is an orally administered “placebo” system containing pharmaceutically inactive ingredients, and the dosage form is designed to have the same appearance as a particular pharmaceutically active dosage form, such as may be used for control purposes in clinical studies to test, for example, the safety and efficacy of a particular pharmaceutically active ingredient.
  • the dosage form of this invention must be molded.
  • the dosage form comprises at least one active ingredient and a confectionery composition.
  • Suitable active ingredients for use in this invention include for example pharmaceuticals, minerals, vitamins and other nutraceuticals, oral care agents, flavorants and mixtures thereof.
  • suitable pharmaceuticals include analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals, anticoagulants, antidepressants, antidiabetic agents, antiemetics, antiflatulents, antifungals, antispasmodics, appetite suppressants, bronchodilators, cardiovascular agents, central nervous system agents, central nervous system stimulants, decongestants, diuretics, expectorants, gastrointestinal agents, migraine preparations, motion sickness products, mucolytics, muscle relaxants, osteoporosis preparations, polydimethylsiloxanes, respiratory agents, sleep-aids, urinary tract agents and mixtures thereof.
  • Suitable oral care agents include breath fresheners, tooth whiteners, antimicrobial agents, tooth mineralizers, tooth decay inhibitors, topical anesthetics, mucoprotectants, and the like.
  • Suitable flavorants include menthol, peppermint, mint flavors, fruit flavors, chocolate, vanilla, bubble gum flavors, coffee flavors, liqueur flavors and combinations and the like.
  • Suitable gastrointestinal agents include antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum sodium carbonate; stimulant laxatives, such as bisacodyl, cascara sagrada, danthron, senna, phenolphthalein, aloe, castor oil, ricinoleic acid, and dehydrocholic acid, and mixtures thereof; H2 receptor antagonists, such as famotadine, ranitidine, cimetadine, nizatidine; proton pump inhibitors such as omeprazole or lansoprazole; gastrointestinal cytoprotectives, such as sucraflate and misoprostol; gastrointestinal prokinetics, such as prucalopride, antibiotics for H.
  • antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum
  • pylori such as clarithromycin, amoxicillin, tetracycline, and metronidazole
  • antidiarrheals such as diphenoxylate and loperamide
  • glycopyrrolate such as glycopyrrolate
  • antiemetics such as ondansetron
  • analgesics such as mesalamine.
  • the active agent may be selected from bisacodyl, famotadine, ranitidine, cimetidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, antacids, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • the active agent is selected from analgesics, anti-inflammatories, and antipyretics: e.g. non-steroidal anti-inflammatory drugs (NSAIDs), including propionic acid derivatives: e.g. ibuprofen, naproxen, ketoprofen and the like; acetic acid derivatives: e.g. indomethacin, diclofenac, sulindac, tolmetin, and the like; fenamic acid derivatives: e.g. mefanamic acid, meclofenamic acid, flufenamic acid, and the like; biphenylcarbodylic acid derivatives: e.g.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • acetic acid derivatives e.g. indomethacin, diclofenac, sulindac, tolmetin, and the like
  • fenamic acid derivatives e.g. mefanamic acid, meclofenamic acid, flufen
  • the active agent is selected from propionic acid derivative NSAID: e.g. ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof.
  • NSAID e.g. ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof.
  • the active agent may be selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • the active agent may be selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • the active agent may be selected from pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, doxylamine, astemizole, terfenadine, fexofenadine, loratadine, desloratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • Suitable polydimethylsiloxanes which include, but are not limited to dimethicone and simethicone, are those disclosed in U.S. Pat. Nos. 4,906,478, 5,275,822, and 6,103,260.
  • simethicone refers to the broader class of polydimethylsiloxanes, including but not limited to simethicone and dimethicone.
  • the active ingredient or ingredients are present in the dosage form in a therapeutically effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular active ingredient being administered, the bioavailability characteristics of the active ingredient, the dose regime, the age and weight of the patient, and other factors must be considered, as known in the art.
  • the dosage form comprises at least about 85 weight percent of the active ingredient.
  • the core comprises at least about 85 weight percent of the active ingredient.
  • the active ingredient or ingredients may be present in the dosage form in any form.
  • the active ingredient may be dispersed at the molecular level, e.g. melted or dissolved, within the dosage form, or may be in the form of particles, which in turn may be coated or uncoated.
  • the particles typically have an average particle size of about 1-2000 microns. In one preferred embodiment, such particles are crystals having an average particle size of about 1-300 microns. In another preferred embodiment, the particles are granules or pellets having an average particle size of about 50-2000 microns, preferably about 50-1000 microns, most preferably about 100-800 microns.
  • the active ingredient may be coated with a taste masking coating, as known in the art.
  • suitable taste masking coatings are described in U.S. Pat. No. 4,851,226, U.S. Pat. No. 5,075,114, and U.S. Pat. No. 5,489,436.
  • Commercially available taste masked active ingredients may also be employed.
  • acetaminophen particles which are encapsulated with ethylcellulose or other polymers by a coaccervation process may be used in the present invention. Coaccervation-encapsulated acetaminophen may be purchased commercially from Eurand America, Inc. (Vandalia, Ohio) or from Circa Inc. (Dayton, Ohio).
  • the dosage form of the invention may also incorporate pharmaceutically acceptable adjuvants, including, for example, preservatives, high intensity sweeteners such as aspartame, acesulfame potassium, cyclamate, saccharin, sucralose, and the like; and other sweeteners such as dihydroalcones, glycyrrhizin, MonellinTM, stevioside, TalinTM, and the like; flavors, antioxidants, surfactants, and coloring agents.
  • pharmaceutically acceptable adjuvants including, for example, preservatives, high intensity sweeteners such as aspartame, acesulfame potassium, cyclamate, saccharin, sucralose, and the like; and other sweeteners such as dihydroalcones, glycyrrhizin, MonellinTM, stevioside, TalinTM, and the like; flavors, antioxidants, surfactants, and coloring agents.
  • the active ingredient may optionally be coated with a release-modifying coating, as is well known in the art.
  • a release-modifying coating as is well known in the art.
  • Commercially available modified release active ingredients may also be employed.
  • acetaminophen particles which are encapsulated with release-modifying polymers by a coaccervation process may be used in the present invention as described above.
  • the active ingredient or ingredients are preferably capable of dissolution upon contact with a fluid such as water, stomach acid, intestinal fluid or the like.
  • the dissolution characteristics of the active ingredient meet USP specifications for immediate release tablets containing the active ingredient.
  • the active ingredient or ingredients are preferably capable of dissolution upon contact with a fluid such as water, stomach acid, intestinal fluid or the like.
  • the dissolution characteristics of the active ingredient meet USP specifications for immediate release tablets containing the active ingredient.
  • USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets, USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. See USP 24 , 2000 Version, 19-20 and 856 (1999).
  • the dissolution characteristics of the active ingredient are modified: e.g. controlled, sustained, extended, retarded, prolonged, delayed and the like.
  • Confectionery composition means an edible product comprising a sweet component.
  • Confectionery compositions generally include medicinal preparations made with sugar, syrup, or honey, and sweet foods such as candy or pastry.
  • suitable confectionery compositions are well known in the art and include “sugar confectionery” such as hard candy (e.g. amorphous sugar-glass, toffees, fudge, fondants, jellies, gummis, pasteils, caramel, taffy, nougat, and chewing gum) as well as “fat-based confectionery” such as chocolate (including, for example, milk chocolate, dark chocolate, semi-sweet chocolate), and coatings including, for example, chocolate compound coatings, pastel compound coatings e.g. white chocolate, and the like.
  • soft candy e.g. amorphous sugar-glass, toffees, fudge, fondants, jellies, gummis, pasteils, caramel, taffy, nougat, and chewing gum
  • fat-based confectionery such as chocolate (including, for example, milk chocolate,
  • Suitable sweet components include sugars such as sucrose, glucose (dextrose), fructose; sugar-alcohols such as sorbitol, mannitol, erythritol, xylitol, maltitol and the like; and high-intensity sweeteners such as aspartame, acesulfame potassium, cyclamate saccharin, sucralose, and the like; and other sweeteners such as dihydroalcones, glycyrrhizin, MonellinTM, stevioside, TalinTM, and the like.
  • the confectionery composition may be selected from fat-based confectionery compositions, such as chocolate, including, for example, milk chocolate, dark chocolate, semi-sweet chocolate; coatings including, for example, chocolate compound coatings, pastel compound coatings e.g. white chocolate, and the like.
  • the fat-based confectionery composition may typically begin to melt at a temperature of about 25 to about 80° C., e.g. about 25 to about 40° C., or about 34 to about 37° C., or about 40 to about 80° C., and comprises a suitable low-melting material.
  • Solid-fat index is a method of characterizing fat blends related to proportion of liquid fat in the blend at different temperatures.
  • IUPAC method 2.141 “Determination of the Dilatation of Fats” details the method for measuring this index.
  • suitable low-melting materials include triglycerides such as lauric and non-lauric cocoa butter substitutes, lauric (shorter chain fatty acids) fats, such as coconut and palm kernal oils and derivatives thereof; non-lauric (longer chain fatty acids) fats such as cocoa butter, palm oil, soybean and cottonseed oils, and derivatives thereof; cocoa butter equivalents; mono, and diglycerides; phospholipids; and water soluble polymers such as polyethylene glycol.
  • the low-melting material is a fractionated lauric fat selected from palm kernal oil and coconut oil.
  • suitable low-melting materials include waxes such as carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax, water soluble polymers such as polyethylene glycol, polyethylene oxides and derivatives, and sucrose esters.
  • the confectionery composition may be a fondant.
  • the confectionery composition comprises a crystalline carbohydrate of which at least about 90% of the crystals have an average size from about 2 to about 15 microns, and typically has a moisture content of about 5 to about 15%, e.g. about 10 to about 12%.
  • the confectionery composition comprises at least one component selected from fat, amorphous sugar glass and fondant.
  • the dosage form of this invention may have any shape that is suitable for molding.
  • the dosage form may be in the shape of a truncated cone.
  • the dosage form may be shaped as a polyhedron, such as a cube, pyramid, prism, or the like; or may have the geometry of a space figure with some non-flat faces, such as a cone, cylinder, sphere, torus, or the like.
  • Exemplary shapes which may be employed include tablet shapes formed from compression tooling shapes described by “The Elizabeth Companies Tablet Design Training Manual” (Elizabeth Carbide Die Co., Inc., p.7 (McKeesport, Pa.) (incorporated herein by reference) as follows (the tablet shape corresponds inversely to the shape of the compression tooling):
  • the dosage form surface may be substantially smooth, i.e. may have indentations or protrusions at the microscopic level on the order of less than about 20 microns in width, depth, or height.
  • the dosage form surface may be textured, i.e. having indentations or protrusions greater than about 20 microns, e.g. greater than about 50 microns, or greater than about 100 microns, say greater than about 1000 microns in width, depth, or height.
  • the indentations or protrusions may be up to about 30,000 microns, e.g. up to about 2,000 microns in width, depth, or height.
  • the outer surface of the dosage form may contain an embossed (raised) or debossed (indented) design.
  • the outer surface of the core may contain indentations, intagliations, letters, symbols or a pattern such as a graphic or logo.
  • the dosage form has at least one face, and the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%.
  • relative standard deviation of the weight of the dosage form may be determined as follows: The weights of 30 individual dosage forms are determined to the nearest 0.1 milligram using an analytical balance. From the 30 individual weights for each sample, a mean, sample standard deviation, and relative standard deviation (% RSD) are calculated, as set forth in Example 5 herein. The relative standard deviation is the standard deviation expressed as a percentage of the mean, as is well known in the art.
  • the dosage form has at least one face, the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%, and the confectionery composition does not contain a gelatin based composition or a gel based composition.
  • the dosage form has at least one face, the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%, the dosage form does not have a free formed surface, and the confectionery composition comprises an amorphous glass sugar component.
  • the dosage form has at least one face, and the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%, and all the faces of the dosage form have a surface gloss of about 200-300 gloss units.
  • surface gloss means a measure of reflected light determined according to the method set forth in Example 4 herein.
  • the dosage form has more than one face, the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%, and the difference in surface gloss between any two faces is not more than about 20 gloss units, preferably about 15 gloss units, more preferably about 10 gloss units.
  • the dosage form has at least one face, the relative standard deviation of the weight of the dosage form is less-than 1%, preferably less than 0.5%, and the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • “Mean polarized light-transmission” as used herein is measured according the method set forth in Example 6 herein.
  • the system for measuring the mean polarized light transmission consists of a light source followed by a first polarizing filter, followed by the sample, followed by a second polarizing filter, followed by a detector, such as, for example, a digital camera.
  • the “angle of maximum transmission” as used herein is the relative position of the polarizers that allows the maximum amount of light to pass through the sample. This has been found to be an angle of approximately zero degrees between the first and second polarizers.
  • the “angle of maximum extinction” as used herein is the relative position of the polarizers that allows the minimum amount of light to pass through a sample. This has been found to be an angle between the first and second polarizers of approximately 90 degrees, plus or minus about 20 degrees.
  • the angle of maximum extinction will vary with the composition of the sample because different sugar-containing compositions rotate the plane of polarized light by varying amounts, with the average being about minus 15 degrees for a 100% glucose solution which corresponds to an angle of maximum extinction of about 75 degrees between the first and second polarizers.
  • the polarized light transmission is measured by plotting the intensity of transmitted light across the 256 grayscale values of the detected image.
  • the mean polarized light transmission is defined as the grayscale value at the midpoint of the area of peak transmission intensity.
  • the difference between the mean polarized light transmission at the angle of maximum transmission and the mean polarized light transmission at the angle of maximum extinction is referred to herein as the “relative homogeneity index.”
  • a sample which is free of strain lines and air bubbles will have a high relative homogeneity index, while a sample containing strain lines and air bubbles will have a low relative homogeneity index.
  • the dosage form has at least one face, the relative standard deviation of the weight of the dosage from is less than 1%, preferably less than 0.5%, the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission, and the dosage form has a mean polarized light transmission between about 0 to 40 grayscale units at the angle of maximum extinction.
  • the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission, and the relative standard deviation of the weight of the dosage form is less than 1.0%, preferably less than 0.5%, more preferably less than 0.5%.
  • the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission, and the confectionery composition does not contain a gelatin based or gel based composition.
  • the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission and the confectionery composition comprises an amorphous sugar glass component.
  • the dosage form has two or more faces, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission and all of the faces of the dosage form have a surface gloss of about 200-300 gloss units.
  • the dosage form has two or more faces, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission, and the difference in surface gloss between any two faces is not more than about 20 gloss units, preferably about 15 gloss units, most preferably about 10 gloss units.
  • the dosage form comprises a confectionery composition which may be a hard candy, such as for example, an amorphous sugar-glass.
  • the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • the dosage form of this invention is a unitary object, that is, a single, undivided article or product similar to a piece of hard candy, for example.
  • the dosage form of this invention does not contain any seams on its surface.
  • the dosage form of this invention is substantially free of pores having a diameter of 0.5 to 5.0 microns.
  • substantially free it is meant that the dosage form has a pore volume of less than about 0.02 cc/g, preferably less than about 0.01 cc/g, more preferably less than about 0.005 cc/g, in the pore diameter range of 0.5 to 5.0 microns.
  • Typical compressed materials have pore volumes of more than about 0.02 cc/g in this pore diameter range.
  • Pore volume measurements may be obtained using a Quantachrome Instruments PoreMaster 60 mercury intrusion porosimeter and associated computer software program known as “Porowin.” The procedure is documented in the Quantachrome Instruments PoreMaster Operation Manual.
  • the PoreMaster determines both pore volume and pore diameter of a solid or powder by forced intrusion of a non-wetting liquid (mercury), which involves evacuation of the sample in a sample cell (penetrometer), filling the cell with mercury to surround the sample with mercury, applying pressure to the sample cell by: (i) compressed air (up to 50 psi maximum); and (ii) a hydraulic (oil) pressure generator (up to 60000 psi maximum).
  • Intruded volume is measured by a change in the capacitance as mercury moves from outside the sample into its pores under applied pressure.
  • the samples remain in sealed packages or as received in the dessicator until analysis.
  • the vacuum pump is switched on, the mercury vapor cold trap is filled with liquid nitrogen, the compressed gas supply is regulated at 55 psi., and the instrument is turned on and allowed a warm up time of at least 30 minutes.
  • the empty penetrometer cell is assembled as described in the instrument manual and its weight is recorded. The cell is installed in the low pressure station and “evacuation and fill only” is selected from the analysis menu, and the following settings are employed:
  • the cell (filled with mercury) is then removed and weighed.
  • the cell is then emptied into the mercury reservoir, and two tablets from each sample are placed in the cell and the cell is reassembled.
  • the weight of the cell and sample are then recorded.
  • the cell is then installed in the low-pressure station, the low-pressure option is selected from the menu, and the following parameters are set:
  • Composition 1 is a Halls hard candy composition commercially available from Warner-Lambert Co., Morris Plains, N.J.
  • Composition 2 is dosage form according to the invention in which the confectionery composition is amorphous sugar glass.
  • FIG. 1A when viewed under normal polarized light there are no distinguishing differences between Compositions 1 and 2 .
  • FIG. 1A when viewed under normal polarized light there are no distinguishing differences between Compositions 1 and 2 .
  • FIG. 1A when viewed under normal polarized light there are no distinguishing differences between Compositions 1 and 2 .
  • Composition 1B when viewed under polarized light at 90° filtering to the incident light, Composition 1 exhibits birefringence (i.e., refracted light) due to residual strain in the glass portion of the composition, whereas Composition 2 advantageously appears uniform without residual strain.
  • the dosage form of this invention is produced by molding.
  • molding methods are known in the art, however it is preferred that the dosage form be made using the thermal setting molding method and apparatus described in copending U.S. application Ser. No. 09/966, 450, pages 57-63, or the thermal cycle molding method and apparatus described in copending U.S. application Ser. No. 09/966,497, pages 27-51, the disclosures of which are incorporated herein by reference.
  • a starting material comprising the ingredients for the dosage form is injected into a molding chamber and molded into the desired shape.
  • the starting material preferably comprises, in addition to the active ingredient and the confectionary composition, a thermal setting material at a temperature above the melting point of the thermal setting material but below the decomposition temperature of the active ingredient.
  • the starting material is cooled and solidifies in the molding chamber into a shaped pellet (i.e., having the shape of the mold).
  • the starting material must be in flowable form.
  • it may comprise solid particles suspended in a molten matrix, for example a polymer matrix.
  • the starting material may be completely molten or in the form of a paste.
  • the starting material may comprise an active ingredient dissolved in a molten material.
  • the starting material may be made by dissolving a solid in a solvent, and the solvent is then evaporated from the starting material after it has been molded.
  • the thermal setting material may be any edible material that is flowable at a temperature between about 37 and about 250° C., and that is a solid or semi-solid at a temperature between about ⁇ 10° C. and about 35° C.
  • the thermal setting material may comprise all or a portion of the confectionary composition as well, as some of the same materials are useful for both.
  • Preferred thermal setting materials include water-soluble polymers such as polyalkylene glycols, polyethylene oxides and derivatives, and sucrose esters; fats such as cocoa butter, hydrogenated vegetable oil such as palm kernel oil, cottonseed oil, sunflower oil, and soybean oil; free fatty acids and their salts; mono- di- and triglycerides, phospholipids, waxes such as camuba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; sugar in the form on an amorphous glass, sugar in a supersaturated solution,; low-moisture polymer solutions such as mixtures of gelatin and other hydrocolloids at water contents up to about 30% such as those used to make “gummi” confection forms.
  • the thermal setting material is a blend of fats and mono- and diglycerides.
  • thermal cycle molding module 200 comprises a rotor 202 around which a plurality of mold units 204 are disposed.
  • the thermal cycle molding module includes a reservoir 206 (see FIG. 4 ) for holding flowable material to make the core.
  • the thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units.
  • FIGS. 55 and 56 of the '497 application depict the temperature control system 600 .
  • the mold units preferably comprise center mold assemblies 212 and upper mold assemblies 214 as shown in FIG. 26C of U.S. patent application Ser. No. 09/966,497, which mate to form mold cavities having the desired shape of the dosage form.
  • the opposing center and upper mold assemblies close.
  • Flowable material comprising the ingredients of the dosage form, which is heated to a flowable state in reservoir 206 , is injected into the resulting mold cavities.
  • the temperature of the flowable material is then decreased, hardening the flowable material into dosage forms.
  • the mold assemblies open and eject the dosage forms.
  • FIG. 2A is a photograph of a two-piece hard candy lozenge mold which may be used to prepare the dosage form of this invention.
  • the mold in FIG. 2A is a 2-piece aluminum mold made up of first mold piece 2 and second mold piece 4 .
  • Mold pieces 2 and 4 have respective cavity portions 6 and 8 which form a cavity which has been polished to a mirror finish.
  • Mold pieces 2 and 4 also have respective injection port portions 12 and 14 which define an injection port for injecting flowable material into the mold, as well as vent port portions 16 and 18 for venting air.
  • FIG. 2B is a photograph of the mold depicted in FIG. 2A together with a lozenge dosage form 10 which has been removed from the mold.
  • a batch of molded hard candy lozenges was prepared in the following manner:
  • the corn syrup was weighed into a tared non-stick 2-quart saucepan. Purified water was then added to the same pan and the mixture was warmed over low heat with stirring until homogeneous. To the diluted corn syrup, dry granular sugar was added and stirred to form a wet slurry.
  • the sugar, water, corn syrup mixture was heated rapidly on a gas-fired stove over high heat with gentle stirring until the mixture appeared clear and began to boil. Heating continued until the mixture reached a temperature of 120° C. at which point the heat was reduced to a medium flame. Heating was continued over a medium flame until 140° C. was reached at which point the color was added to the batch and stirred in until uniformly distributed. When the temperature reached 145° C., the batch was removed from the stove and the flavor was blended into the batch. Subsequently, the batch was allowed to cool slightly without mixing so that air bubbles would dissipate.
  • the molten candy base was injected into a two piece metal mold held together by thumbscrews (as shown in FIGS. 2A and 2B ).
  • the mold constructed from aluminum, had an injection port and a vent port that allowed excess candy mass to exit the mold.
  • the fill cavity in the shape of the desired lozenge piece, was polished to provide a molded dosage form having a smooth shiny surface.
  • the injection device a 10 cc plastic syringe having a cut off tip, was used to transfer candy base from the cooked batch and inject the candy base into the injection port of the molding apparatus. Once filled, the mold was allowed to cool at room temperature for about 2 minutes before opening. Upon opening, the molded dosage form was removed and any excess hard candy web from the fill and vent ports was snapped off.
  • a dosage form according to the invention is made following the procedure stated in Example 1, except the hard candy pre-cook formation is as follows: Ingredient % mg/tab gms/batch Corn Syrup (42 DE) 44.99 170.06 498.85 Sugar (dry granular) 44.99 170.06 498.85 Purified Water USP 8.98 33.93 99.60 FD&C Red #40 0.05 0.20 0.50 Flavor 0.20 0.75 2.20 Benzydamine 0.79 3.00 8.80 TOTAL 100.00 378.00 1108.8 Here, the active ingredient, benzydamine, is added along with the flavor after the batch is removed from the stove.
  • a commercial scale batch of hard candy menthol dosage forms according to the invention is made using thermal cycle molding and the formulation set forth below:
  • Sucrose, corn syrup and water from the pre-cook formulation is vacuum cooked by a batch method.
  • Other suitable methods include semicontinuous, and continuous vacuum cooking.
  • Confectionery vacuum cookers are manufactured by APV Baker (Peterborough, UK), Kloeckner-Hansel GmbH (Cape Coral, Fla.), and Hosokawa Ter Braak B. V. (Rotterdam, Netherlands).
  • the cooked hard candy batch is transferred to heated supply tanks or reservoirs, such as those shown as 206 in FIG. 4 of copending U.S. application Ser. No. 09/966,497.
  • the cooked hard candy batch is maintained within the reservoirs at about 120° C. without stirring.
  • the reservoirs 206 are covered and pressurized to about 150 psi or sufficient pressure to allow the fluid hard candy mass to flow to a thermal cycle molding module as follows.
  • the dosage forms are then made in a thermal cycle molding module thermal cycle molding module having the specific configuration shown in FIG. 26A of copending U.S. application Ser. No. 09/966,497.
  • the thermal cycle molding module comprises center mold assemblies 212 and upper mold assemblies 214 as shown in FIG. 26C , which mate to form mold cavities having the shape of a hard candy.
  • center mold assemblies 212 and upper mold assemblies 214 as shown in FIG. 26C , which mate to form mold cavities having the shape of a hard candy.
  • the opposing center and upper mold assemblies close.
  • the fluid, cooked hard candy batch is injected into the resulting mold cavities.
  • the mold assemblies are thermally cycled between about 120° C. and about 90° C. and receive the hot cooked hard candy batch material when its cycle is in the high temperature range. As the hot material fills the mold cavity, the mold temperature is cycled to the low temperature range (i.e. 60-90° C.) and cools the material to a temperature where it is sufficiently solid that it no longer flows under its own weight. Once set (i.e., for 1-60 seconds), the mold assemblies open and the molded dosage form is ejected from the thermal cycle molding module and conveyed to a tray to cool and completely harden.
  • a batch of molded hard candy lozenge dosage forms is ready to be transferred in bulk to a packaging line.
  • TriCor Systems Inc. (Elgin, Ill.) under the tradename, “TRI-COR MODEL 805A/806H SURFACE ANALYSIS SYSTEM” and generally in accordance with the procedure described in “TriCor Systems WGLOSS 3.4 Model 805A/806H Surface Analysis System Reference Manual” (1996), which is incorporated by reference herein, except as modified below,
  • This instrument utilized a CCD camera detector, employed a flat diffuse light source, compared tablet samples to a reference standard, and determined average gloss values at a 60 degree incident angle. During its operation, the instrument generated a gray-scale image, wherein the occurrence of brighter pixels indicated the presence of more gloss at that given location.
  • the instrument also incorporated software that utilized a grouping method to quantify gloss, i.e., pixels with similar brightness were grouped together for averaging purposes.
  • the “percent full scale” or “percent ideal” setting (also referred to as the “percent sample group” setting), was specified by the user to designate the portion of the brightest pixels above the threshold that will be considered as one group and averaged within that group.
  • threshold is defined as the maximum gloss value that will not be included in the average gloss value calculation. Thus, the background, or the non-glossy areas of a sample were excluded from the average gloss value calculations.
  • each face of each sample molded lozenge was then independently tested in accordance with the same procedure.
  • the “free-formed” face was designated as “Face 1.”
  • the opposing face was designated as “Face 2”.
  • a 31 by 31 pixel area (corresponding to an area on the sample of about 3.1 mm ⁇ 3.1 mm, or 9.61 square millimeters) was chosen to minimize contribution from air bubbles.
  • HALLS PLUS lozenges available from Warner-Lambert Company, Morris Plains, N.J. were selected as exemplary of lozenges manufactured by a conventional uniplasting process (Sample A).
  • Cepacol® Sore Throat Lozenges available from J. B.
  • Example D Injection molded lozenges made according to the method of Example 1 were designated as Sample D.
  • lozenge-type dosage forms according to the invention have a small difference in surface gloss between the two faces.
  • commercially available lozenges molded by depositing had surface glosses on their free-formed faces at least about 21 gloss units higher than the surface gloss on their molded faces.
  • Lozenges made by the Uniplast punch method also showed less difference in surface gloss between their 2 major faces than those prepared by depositing.
  • Variation in piece weight of various commercially available confectionery forms was measured by the following method.
  • the weight of 30 individual pieces of each form was determined to the nearest 0.1 milligram using an analytical balance. From the 30 individual piece weights for each sample, a mean, sample standard deviation, and relative standard deviation (% RSD) were calculated. Note the relative standard deviation is the standard deviation expressed as a percentage of the mean, as known in the art.
  • Samples of hard candy glass were viewed and photographed under plane polarized light to quantify the relative strain in the candy glass.
  • Sample A was a Halls Plus® lozenge commercially available from Warner-Lambert Co., Morris Plains, N.J.
  • Sample B was an injection molded lozenge made according to Example 1 herein.
  • Sample C was a Chloraseptic lozenge commercially available from Prestige Brands International, Inc., Bonita Springs, Fla.
  • Samples A and C are exemplary of UniplastTM punch molded hard candy glass products. Typically, injection molded and deposited hard candy show no intrinsic strain whereas punch or roller molded hard candy retain residual strain that is visible when viewed under a strain viewer.
  • the equipment used was as follows:
  • a first filter 300 was secured to the middle of a light box 302 with cellophane tape and a second filter 304 was held by hand, parallel above the first filter 302 .
  • Samples ( 306 and 308 ) being analyzed were placed on top of the first filter 300 but beneath the second filter 304 .
  • Light transmission was regulated by rotating the second filter 304 while maintaining its parallel position above the first filter 300 , as shown in FIG. 3B .
  • strain viewers are commercially available from: Strainoptic Technologies, Inc., 108 W. Montgomery Ave., North Wales, Pa. 19454, or from Sharples Stress Engineers, LTD, Unit 29 Old Mill Industrial Estate, School Lane, PR5 6SY Lancashire, UK.
  • Photographs of the samples were recorded using a digital camera. The pictures were taken through the second filter at both the maximum light transmission angle and the minimum light transmission angle (maximum extinction) with respect to the sample image (not the filter).
  • FIGS. 4A and 4B depict typical photographic images for a punch molded hard candy (Sample A) and an injection molded or deposited hard candy (Sample B) when viewed as described at maximum and minimum light transmission through a pair of polarizing filters.
  • image analysis software Sigma Scan Pro 5 available from SPSS, Inc.
  • SPSS, Inc. image analysis software
  • Equivalent areas of the color images were converted into gray scale and displayed as a histogram of pixel elements ranging in value from 0 (black) to 255 (white).
  • sample illumination and digital image exposure is adjusted to maximize the peak separation between the transmission and extinction states.
  • a converted image appears as a peak-like distribution of gray scale pixels.
  • the peak maximum for a given sample differs when the polarization filters are at maximum light transmission (0°) versus maximum light extinction ( ⁇ 90°).
  • Drop roll or punch molded hard candy samples such as the Chloraceptic® Lozenge (Sample C) depicted in FIG. 5 , brighten as polarization reaches the point of maximum extinction and their gray scale peaks shift to higher values.
  • their images darken and their gray scale peaks shift to smaller values as the polarized light reaches high extinction levels.

Abstract

A dosage form comprises an active ingredient and a confectionery composition. In one embodiment the relative standard deviation of the weight of the dosage form is less than 1%, and the dosage form has at least one face. In another embodiment, a dosage form comprising an active ingredient and a confectionery composition wherein the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission. The active ingredient may be a pharmaceutically active agent.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention relates to dosage forms such as pharmaceutical compositions comprising a confectionery composition. More particularly, this invention relates to dosage forms containing at least one active ingredient and a confectionery composition such as fat, amorphous sugar glass, or fondant.
  • 2. Background Information
  • An important objective in designing pharmaceutical drug delivery systems, especially for pediatric and geriatric applications, is to make palatable, good tasting, dosage forms which mask the unpleasant taste and/or texture of the active pharmaceutical ingredient, to improve patient compliance with the dosing regimen. Confectionery compositions offer great potential for achieving these desired product attributes; however their use in pharmaceutical applications has to date been quite limited.
  • The substantial differences in regulations governing the confectionery and pharmaceutical industries has led to both facilities and processes that are not directly transferable between the two. The pharmaceutical developer desiring to apply the benefits of confectionery compositions to drug delivery systems must overcome major challenges in the areas of pharmaceutical “good manufacturing practices” (GMP) and product quality standards.
  • Confectionery manufacturing facilities, for example, are not commonly designed to allow for the rigorous controls on raw material traceability required by the pharmaceutical industry, or equipped for avoiding cross-contamination while processing multiple drug active ingredients. A high-purity water source, closed air-handling system, and on-site analytical laboratory are critical for any pharmaceutical operation. Installing and validating these systems entails substantial cost and complexity.
  • Most current commercial confectionery processes are designed to meet the primary objectives of high-volume and low cost, while aesthetic properties, consistency, uniformity, precision of dose, and general appearance are secondary considerations. For pharmaceutical dosage forms, there is a need for relatively low-cost, high volume commercial scale processing methods which also reliably and repeatably produce a highly precise dose which is also a uniform, consistent, elegant looking product.
  • In typical current confectionery processes, for example, a high percentage of scrap may be generated during processing without compromising efficiency, because the unused portion of a batch can be recycled into a future batch. In pharmaceutical processes, it would not be considered GMP to routinely re-process waste, or co-mingle batches.
  • Pharmaceutical dosage forms must have minimal variation in the weight of individual dosage units to achieve a high degree of drug content uniformity. Since many confectionery processes were designed without the need for the high degree of precision and reproducibility required for pharmaceuticals, a high degree of variation is inherent in their design. Typical confectionery rope-forming operations, for example, result in high product weight variation due to entrained air, and variations in rope tensile strength, viscosity, and plasticity with temperature. Conventional confectionery cut and wrap operations result in high product weight variation due to variation in flow and thickness of the rope. Extruded confectionery compositions can vary in piece weight due to changes in flow rate, and pulsations in the center fill pumping operation which lead to variations in center fill content. Additionally high weight variation is inherent in confectionery depositing operations, which do not fill a fixed volume, so piece weight depends on the reproducibility of the metered dose pumping, which is subject to variability in viscosity, due to temperature and material factors.
  • Product aesthetics represent another area of discrepancy between the two industries. For example, typical confectionery depositing operations produce a product which can have high definition on only three sides, but necessarily has a “free-formed” surface on one side. In such products, the degree of surface gloss is higher on the free-formed surface than the molded sides. Pharmaceutical products typically require a uniform and consistent appearance implying a high degree of control in the manufacturing process. It is thus desirable to have a manufacturing process which can provide uniform high definition on all sides of the dosage form.
  • The products produced by current confectionery methods are not designed to withstand conventional packaging operations without a substantial level of chipping, cracking, deformation, or breakage, which would be unacceptable for pharmaceutical dosage forms. For example typical rope forming operations entrain air during the cooling and folding operations, and impart mechanical stress to the glass during the roping operation. These imperfections manifest as strain lines and air bubbles in the finished product, which result in higher product fragility, decreased product uniformity, and decreased visual appeal. In particular, the areas of strain can serve as nucleation sites for crystal formation, which decreases the shelf life of the product. Entrained air additionally results in weight variation, and detracts from overall consistency and visual elegance of the product.
  • Chocolate-coatings over confectionery cores are typically made by filling a cold mold to solidify the outer layer of chocolate, then pouring out the excess, then injecting with the center fill material, or alternatively by dipping the core material into molten chocolate to form the bottom, then enrobing the remainder of the piece by pouring molten chocolate over the top and sides, then dripping off the excess. Such operations are inherently high in weight variation because the coating level depends upon the viscosity of the chocolate which will vary with raw materials, temperature, humidity, etc. Thus these operations do not lend themselves to pharmaceutical dosage forms. A need exists for manufacturing processes which enable the reliable and repeatable formation of a precise and consistent level of chocolate coating over any type of center fill, to realize the benefits of these types of compositions for pharmaceutical applications.
  • It is one object of this invention to provide a dosage form comprising an active ingredient and a confectionery composition wherein the relative standard deviation of the weight of the dosage form is less than 1%, and the dosage form has at least one face.
  • It is another object of this invention to provide a dosage form comprising an active ingredient and a confectionery composition wherein the dosage form has at least one face, the dosage form does not have a free formed surface, and the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • Other objects, features and advantages of this invention will be apparent to these skilled in the art from the detailed description of the invention provided herein.
  • SUMMARY OF THE INVENTION
  • In one embodiment, the dosage form of this invention comprises at least one active ingredient and a confectionery composition, the dosage form has at least one face, and the relative standard deviation of the weight of the dosage form is less than 1%, preferably 0.5%.
  • In another embodiment of this invention, the dosage form comprises at least one active ingredient and a confectionery composition wherein the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • In another embodiment, the relative standard deviation of the weight of the dosage form is less than 0.5%.
  • In another embodiment, the confectionery composition comprises at least one component selected from the group consisting of fat, amorphous sugar glass and fondant.
  • In another embodiment, the confectionery composition does not contain a gelatin based composition.
  • In another embodiment, the confectionery composition does not contain a gel based composition.
  • In another embodiment, the confectionery composition comprises an amorphous sugar glass component and the dosage form does not have a free formed surface.
  • In another embodiment, all the faces of the dosage form have a surface gloss of about 200-300 gloss units.
  • In another embodiment, the dosage form has two or more faces, and the difference in surface gloss between any two faces is not more than about 20 gloss units.
  • In another embodiment, the difference in surface gloss between any two faces is not more than about 15 gloss units.
  • In another embodiment, the difference in surface gloss between any two faces is not more than about 10 gloss units.
  • In another embodiment, the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • In another embodiment, the dosage form has a mean polarized light transmission between about 0 to 40 grayscale units at the angle of maximum extinction.
  • In another embodiment, the confectionery composition comprises an amorphous sugar glass component and the dosage form does not have a free formed surface.
  • In another embodiment, the active ingredient is a pharmaceutically active ingredient.
  • In another embodiment, the dosage form comprises particles which comprise the active ingredient.
  • In another embodiment, the particles have an average particle size of about 50 to about 2000 microns.
  • In another embodiment, at least a portion of the particles are coated particles.
  • In another embodiment, the dosage form is a unitary object.
  • In another embodiment, the dosage form does not contain any seams on its surface.
  • In another embodiment, the relative standard deviation of the weight of the dosage form is less than 1.0%.
  • In another embodiment, the confectionery composition comprises an amorphous sugar glass component.
  • In another embodiment, the dosage form is substantially free of pores having a diameter of 0.5 to 5.0 microns.
  • In another embodiment, the dosage form of this invention does not contain a gel-based composition or a gelatin-based composition.
  • In another embodiment, the dosage form of this invention comprises an amorphous sugar glass component and the dosage form does not have a free formed surface.
  • In another embodiment, all the dosage form faces have a surface gloss of about 200-300 gloss units.
  • In another embodiment, the dosage form has two or more faces, and the difference in surface gloss between any two faces is not more than about 20 gloss units, preferably not more than about 15 gloss units, most preferably not more than about 10 gloss units.
  • In another embodiment, the dosage form has a mean polarized light transmission between about 0 to 40 grayscale units at the angle of maximum extinction.
  • In another embodiment, the active ingredient is a pharmaceutically active ingredient.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A depicts a prior art composition and a composition of the present invention viewed under normal polarized light.
  • FIG. 1B depicts a prior art composition and a composition of the present invention viewed under polarized light at 90° filtering to the incident light.
  • FIG. 2A is a photograph of a two-piece hard candy lozenge mold which may be used to prepare the dosage form of this invention.
  • FIG. 2B is a photograph of the mold depicted in FIG. 2A together with a lozenge dosage form which has been removed from the mold.
  • FIG. 3A depicts an apparatus for measuring mean polarized light transmission at the angle of maximum transmission.
  • FIG. 3B depicts an apparatus for measuring mean polarized light transmission at the angle of maximum extinction.
  • FIG. 4A depicts typical photographic images taken at the angle of maximum light transmission comparing hard candies made by methods of the prior art and the dosage form of this invention.
  • FIG. 4B depicts typical photographic images taken at the angle of maximum light extinction comparing hard candies made by methods of the prior art and the dosage form of this invention.
  • FIG. 5 shows the greyscale intensity distribution for a CHLORASEPTIC throat lozenge at both the angle of maximum light transmission and the angle of maximum light extinction.
  • FIG. 6 shows the greyscale intensity distribution for the product of the present invention at both the angle of maximum light transmission and the angle of maximum light extinction.
  • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein, the term “dosage form” applies to any solid object, semi-solid, or liquid composition, designed to contain a specific predetermined amount (i.e. dose) of a certain ingredient, for example an active ingredient as defined below. Suitable dosage forms may be pharmaceutical drug delivery systems, including those for oral administration, buccal administration, rectal administration, topical, transdermal, or mucosal delivery, or subcutaneous implants, or other implanted drug delivery systems; or compositions for delivering minerals, vitamins and other nutraceuticals, oral care agents, flavorants, and the like. Preferably the dosage forms of the present invention are considered to be solid, however they may contain liquid or semi-solid components. In a particularly preferred embodiment, the dosage form is an orally administered system for delivering a pharmaceutical active ingredient to the gastro-intestinal tract of a human. In another preferred embodiment, the dosage form is an orally administered “placebo” system containing pharmaceutically inactive ingredients, and the dosage form is designed to have the same appearance as a particular pharmaceutically active dosage form, such as may be used for control purposes in clinical studies to test, for example, the safety and efficacy of a particular pharmaceutically active ingredient.
  • The dosage form of this invention must be molded. The dosage form comprises at least one active ingredient and a confectionery composition.
  • Suitable active ingredients for use in this invention include for example pharmaceuticals, minerals, vitamins and other nutraceuticals, oral care agents, flavorants and mixtures thereof. Suitable pharmaceuticals include analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals, anticoagulants, antidepressants, antidiabetic agents, antiemetics, antiflatulents, antifungals, antispasmodics, appetite suppressants, bronchodilators, cardiovascular agents, central nervous system agents, central nervous system stimulants, decongestants, diuretics, expectorants, gastrointestinal agents, migraine preparations, motion sickness products, mucolytics, muscle relaxants, osteoporosis preparations, polydimethylsiloxanes, respiratory agents, sleep-aids, urinary tract agents and mixtures thereof.
  • Suitable oral care agents include breath fresheners, tooth whiteners, antimicrobial agents, tooth mineralizers, tooth decay inhibitors, topical anesthetics, mucoprotectants, and the like.
  • Suitable flavorants include menthol, peppermint, mint flavors, fruit flavors, chocolate, vanilla, bubble gum flavors, coffee flavors, liqueur flavors and combinations and the like.
  • Examples of suitable gastrointestinal agents include antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum sodium carbonate; stimulant laxatives, such as bisacodyl, cascara sagrada, danthron, senna, phenolphthalein, aloe, castor oil, ricinoleic acid, and dehydrocholic acid, and mixtures thereof; H2 receptor antagonists, such as famotadine, ranitidine, cimetadine, nizatidine; proton pump inhibitors such as omeprazole or lansoprazole; gastrointestinal cytoprotectives, such as sucraflate and misoprostol; gastrointestinal prokinetics, such as prucalopride, antibiotics for H. pylori, such as clarithromycin, amoxicillin, tetracycline, and metronidazole; antidiarrheals, such as diphenoxylate and loperamide; glycopyrrolate; antiemetics, such as ondansetron, analgesics, such as mesalamine.
  • In one embodiment of the invention, the active agent may be selected from bisacodyl, famotadine, ranitidine, cimetidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, antacids, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • In another embodiment, the active agent is selected from analgesics, anti-inflammatories, and antipyretics: e.g. non-steroidal anti-inflammatory drugs (NSAIDs), including propionic acid derivatives: e.g. ibuprofen, naproxen, ketoprofen and the like; acetic acid derivatives: e.g. indomethacin, diclofenac, sulindac, tolmetin, and the like; fenamic acid derivatives: e.g. mefanamic acid, meclofenamic acid, flufenamic acid, and the like; biphenylcarbodylic acid derivatives: e.g. diflunisal, flufenisal, and the like; and oxicams: e.g. piroxicam, sudoxicam, isoxicam, meloxicam, and the like. In a particularly preferred embodiment, the active agent is selected from propionic acid derivative NSAID: e.g. ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof. In another embodiment of the invention, the active agent may be selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof. In another embodiment of the invention, the active agent may be selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • In another embodiment of the invention, the active agent may be selected from pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, doxylamine, astemizole, terfenadine, fexofenadine, loratadine, desloratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • Examples of suitable polydimethylsiloxanes, which include, but are not limited to dimethicone and simethicone, are those disclosed in U.S. Pat. Nos. 4,906,478, 5,275,822, and 6,103,260. As used herein, the term “simethicone” refers to the broader class of polydimethylsiloxanes, including but not limited to simethicone and dimethicone.
  • The active ingredient or ingredients are present in the dosage form in a therapeutically effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular active ingredient being administered, the bioavailability characteristics of the active ingredient, the dose regime, the age and weight of the patient, and other factors must be considered, as known in the art. Preferably, the dosage form comprises at least about 85 weight percent of the active ingredient. In one preferred embodiment, the core comprises at least about 85 weight percent of the active ingredient.
  • The active ingredient or ingredients may be present in the dosage form in any form. For example, the active ingredient may be dispersed at the molecular level, e.g. melted or dissolved, within the dosage form, or may be in the form of particles, which in turn may be coated or uncoated. If the active ingredient is in form of particles, the particles (whether coated or uncoated) typically have an average particle size of about 1-2000 microns. In one preferred embodiment, such particles are crystals having an average particle size of about 1-300 microns. In another preferred embodiment, the particles are granules or pellets having an average particle size of about 50-2000 microns, preferably about 50-1000 microns, most preferably about 100-800 microns.
  • If the active ingredient has an objectionable taste, and the dosage form is intended to be chewed or disintegrated in the mouth prior to swallowing, the active ingredient may be coated with a taste masking coating, as known in the art. Examples of suitable taste masking coatings are described in U.S. Pat. No. 4,851,226, U.S. Pat. No. 5,075,114, and U.S. Pat. No. 5,489,436. Commercially available taste masked active ingredients may also be employed. For example, acetaminophen particles which are encapsulated with ethylcellulose or other polymers by a coaccervation process may be used in the present invention. Coaccervation-encapsulated acetaminophen may be purchased commercially from Eurand America, Inc. (Vandalia, Ohio) or from Circa Inc. (Dayton, Ohio).
  • The dosage form of the invention may also incorporate pharmaceutically acceptable adjuvants, including, for example, preservatives, high intensity sweeteners such as aspartame, acesulfame potassium, cyclamate, saccharin, sucralose, and the like; and other sweeteners such as dihydroalcones, glycyrrhizin, Monellin™, stevioside, Talin™, and the like; flavors, antioxidants, surfactants, and coloring agents.
  • In certain embodiments in which modified release of the active ingredient is desired, the active ingredient may optionally be coated with a release-modifying coating, as is well known in the art. Commercially available modified release active ingredients may also be employed. For example, acetaminophen particles which are encapsulated with release-modifying polymers by a coaccervation process may be used in the present invention as described above.
  • The active ingredient or ingredients are preferably capable of dissolution upon contact with a fluid such as water, stomach acid, intestinal fluid or the like. In a preferred embodiment the dissolution characteristics of the active ingredient meet USP specifications for immediate release tablets containing the active ingredient. In embodiments in which it is desired for the active ingredient to be absorbed into the systemic circulation of an animal, the active ingredient or ingredients are preferably capable of dissolution upon contact with a fluid such as water, stomach acid, intestinal fluid or the like. In one embodiment, the dissolution characteristics of the active ingredient meet USP specifications for immediate release tablets containing the active ingredient. For example, for acetaminophen tablets, USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets, USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. See USP 24, 2000 Version, 19-20 and 856 (1999). In another embodiment, the dissolution characteristics of the active ingredient are modified: e.g. controlled, sustained, extended, retarded, prolonged, delayed and the like.
  • As used herein, the term “confectionery composition” means an edible product comprising a sweet component. Confectionery compositions generally include medicinal preparations made with sugar, syrup, or honey, and sweet foods such as candy or pastry. Suitable confectionery compositions are well known in the art and include “sugar confectionery” such as hard candy (e.g. amorphous sugar-glass, toffees, fudge, fondants, jellies, gummis, pasteils, caramel, taffy, nougat, and chewing gum) as well as “fat-based confectionery” such as chocolate (including, for example, milk chocolate, dark chocolate, semi-sweet chocolate), and coatings including, for example, chocolate compound coatings, pastel compound coatings e.g. white chocolate, and the like.
  • Suitable sweet components include sugars such as sucrose, glucose (dextrose), fructose; sugar-alcohols such as sorbitol, mannitol, erythritol, xylitol, maltitol and the like; and high-intensity sweeteners such as aspartame, acesulfame potassium, cyclamate saccharin, sucralose, and the like; and other sweeteners such as dihydroalcones, glycyrrhizin, Monellin™, stevioside, Talin™, and the like.
  • In another embodiment, the confectionery composition may be selected from fat-based confectionery compositions, such as chocolate, including, for example, milk chocolate, dark chocolate, semi-sweet chocolate; coatings including, for example, chocolate compound coatings, pastel compound coatings e.g. white chocolate, and the like. In such embodiments, the fat-based confectionery composition may typically begin to melt at a temperature of about 25 to about 80° C., e.g. about 25 to about 40° C., or about 34 to about 37° C., or about 40 to about 80° C., and comprises a suitable low-melting material. Those skilled in the art will recognize that the melting point of the composition may vary according to the solid-fat indices of the various fat components. Solid-fat index (SFI) is a method of characterizing fat blends related to proportion of liquid fat in the blend at different temperatures. IUPAC method 2.141 “Determination of the Dilatation of Fats” details the method for measuring this index.
  • In embodiments where the confectionery composition begins to melt between 25-40° C., suitable low-melting materials include triglycerides such as lauric and non-lauric cocoa butter substitutes, lauric (shorter chain fatty acids) fats, such as coconut and palm kernal oils and derivatives thereof; non-lauric (longer chain fatty acids) fats such as cocoa butter, palm oil, soybean and cottonseed oils, and derivatives thereof; cocoa butter equivalents; mono, and diglycerides; phospholipids; and water soluble polymers such as polyethylene glycol. In one embodiment, the low-melting material is a fractionated lauric fat selected from palm kernal oil and coconut oil.
  • In embodiments where the composition begins to melt between 40-80° C., suitable low-melting materials include waxes such as carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax, water soluble polymers such as polyethylene glycol, polyethylene oxides and derivatives, and sucrose esters.
  • In yet another embodiment, the confectionery composition may be a fondant. In such embodiments, the confectionery composition comprises a crystalline carbohydrate of which at least about 90% of the crystals have an average size from about 2 to about 15 microns, and typically has a moisture content of about 5 to about 15%, e.g. about 10 to about 12%.
  • In a preferred embodiment, the confectionery composition comprises at least one component selected from fat, amorphous sugar glass and fondant.
  • The dosage form of this invention may have any shape that is suitable for molding. For example, in one embodiment the dosage form may be in the shape of a truncated cone. In other embodiments the dosage form may be shaped as a polyhedron, such as a cube, pyramid, prism, or the like; or may have the geometry of a space figure with some non-flat faces, such as a cone, cylinder, sphere, torus, or the like. Exemplary shapes which may be employed include tablet shapes formed from compression tooling shapes described by “The Elizabeth Companies Tablet Design Training Manual” (Elizabeth Carbide Die Co., Inc., p.7 (McKeesport, Pa.) (incorporated herein by reference) as follows (the tablet shape corresponds inversely to the shape of the compression tooling):
      • 1. Shallow Concave.
      • 2. Standard Concave.
      • 3. Deep Concave.
      • 4. Extra Deep Concave.
      • 5. Modified Ball Concave.
      • 6. Standard Concave Bisect.
      • 7. Standard Concave Double Bisect.
      • 8. Standard Concave European Bisect.
      • 9. Standard Concave Partial Bisect.
      • 10. Double Radius.
      • 11. Bevel & Concave.
      • 12. Flat Plain.
      • 13. Flat-Faced-Beveled Edge (F.F.B.E.).
      • 14. F.F.B.E. Bisect.
      • 15. F.F.B.E. Double Bisect.
      • 16. Ring.
      • 17. Dimple.
      • 18. Ellipse.
      • 19. Oval.
      • 20. Capsule.
      • 21. Rectangle.
      • 22. Square.
      • 23. Triangle.
      • 24. Hexagon.
      • 25. Pentagon.
      • 26. Octagon.
      • 27. Diamond.
      • 28. Arrowhead.
      • 29. Bullet.
      • 30. Barrel.
      • 31. Half Moon.
      • 32. Shield.
      • 33. Heart.
      • 34. Almond.
      • 35. House/Home Plate.
      • 36. Parallelogram.
      • 37. Trapezoid.
      • 38. FIG. 8/Bar Bell.
      • 39. Bow Tie.
      • 40. Uneven Triangle.
  • The dosage form surface may be substantially smooth, i.e. may have indentations or protrusions at the microscopic level on the order of less than about 20 microns in width, depth, or height. Alternately the dosage form surface may be textured, i.e. having indentations or protrusions greater than about 20 microns, e.g. greater than about 50 microns, or greater than about 100 microns, say greater than about 1000 microns in width, depth, or height. The indentations or protrusions may be up to about 30,000 microns, e.g. up to about 2,000 microns in width, depth, or height. In embodiments wherein the dosage form surface is textured, the outer surface of the dosage form may contain an embossed (raised) or debossed (indented) design. For example, the outer surface of the core may contain indentations, intagliations, letters, symbols or a pattern such as a graphic or logo.
  • In one embodiment of this invention, the dosage form has at least one face, and the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%. As used herein, relative standard deviation of the weight of the dosage form may be determined as follows: The weights of 30 individual dosage forms are determined to the nearest 0.1 milligram using an analytical balance. From the 30 individual weights for each sample, a mean, sample standard deviation, and relative standard deviation (% RSD) are calculated, as set forth in Example 5 herein. The relative standard deviation is the standard deviation expressed as a percentage of the mean, as is well known in the art.
  • In another embodiment of this invention, the dosage form has at least one face, the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%, and the confectionery composition does not contain a gelatin based composition or a gel based composition.
  • In another embodiment of this invention, the dosage form has at least one face, the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%, the dosage form does not have a free formed surface, and the confectionery composition comprises an amorphous glass sugar component.
  • In another embodiment of this invention, the dosage form has at least one face, and the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%, and all the faces of the dosage form have a surface gloss of about 200-300 gloss units. As used herein, “surface gloss” means a measure of reflected light determined according to the method set forth in Example 4 herein.
  • In another embodiment of this invention, the dosage form has more than one face, the relative standard deviation of the weight of the dosage form is less than 1%, preferably less than 0.5%, and the difference in surface gloss between any two faces is not more than about 20 gloss units, preferably about 15 gloss units, more preferably about 10 gloss units.
  • In another embodiment of this invention, the dosage form has at least one face, the relative standard deviation of the weight of the dosage form is less-than 1%, preferably less than 0.5%, and the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • “Mean polarized light-transmission” as used herein is measured according the method set forth in Example 6 herein. In summary, the system for measuring the mean polarized light transmission consists of a light source followed by a first polarizing filter, followed by the sample, followed by a second polarizing filter, followed by a detector, such as, for example, a digital camera.
  • The “angle of maximum transmission” as used herein is the relative position of the polarizers that allows the maximum amount of light to pass through the sample. This has been found to be an angle of approximately zero degrees between the first and second polarizers.
  • The “angle of maximum extinction” as used herein is the relative position of the polarizers that allows the minimum amount of light to pass through a sample. This has been found to be an angle between the first and second polarizers of approximately 90 degrees, plus or minus about 20 degrees. The angle of maximum extinction will vary with the composition of the sample because different sugar-containing compositions rotate the plane of polarized light by varying amounts, with the average being about minus 15 degrees for a 100% glucose solution which corresponds to an angle of maximum extinction of about 75 degrees between the first and second polarizers.
  • The polarized light transmission is measured by plotting the intensity of transmitted light across the 256 grayscale values of the detected image. The mean polarized light transmission is defined as the grayscale value at the midpoint of the area of peak transmission intensity. The difference between the mean polarized light transmission at the angle of maximum transmission and the mean polarized light transmission at the angle of maximum extinction is referred to herein as the “relative homogeneity index.” A sample which is free of strain lines and air bubbles will have a high relative homogeneity index, while a sample containing strain lines and air bubbles will have a low relative homogeneity index.
  • In another embodiment of this invention, the dosage form has at least one face, the relative standard deviation of the weight of the dosage from is less than 1%, preferably less than 0.5%, the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission, and the dosage form has a mean polarized light transmission between about 0 to 40 grayscale units at the angle of maximum extinction.
  • In another embodiment of this invention, the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • In another embodiment of this invention, the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission, and the relative standard deviation of the weight of the dosage form is less than 1.0%, preferably less than 0.5%, more preferably less than 0.5%.
  • In another embodiment of this invention, the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission, and the confectionery composition does not contain a gelatin based or gel based composition.
  • In another embodiment of this invention, the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission and the confectionery composition comprises an amorphous sugar glass component.
  • In another embodiment of this invention, the dosage form has two or more faces, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission and all of the faces of the dosage form have a surface gloss of about 200-300 gloss units.
  • In another embodiment of this invention, the dosage form has two or more faces, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission, and the difference in surface gloss between any two faces is not more than about 20 gloss units, preferably about 15 gloss units, most preferably about 10 gloss units.
  • In another embodiment, the dosage form comprises a confectionery composition which may be a hard candy, such as for example, an amorphous sugar-glass. In such embodiments the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
  • In another embodiment, the dosage form of this invention is a unitary object, that is, a single, undivided article or product similar to a piece of hard candy, for example.
  • In another preferred embodiment, the dosage form of this invention does not contain any seams on its surface.
  • In other embodiments, the dosage form of this invention is substantially free of pores having a diameter of 0.5 to 5.0 microns. By “substantially free” it is meant that the dosage form has a pore volume of less than about 0.02 cc/g, preferably less than about 0.01 cc/g, more preferably less than about 0.005 cc/g, in the pore diameter range of 0.5 to 5.0 microns. Typical compressed materials have pore volumes of more than about 0.02 cc/g in this pore diameter range.
  • Pore volume measurements may be obtained using a Quantachrome Instruments PoreMaster 60 mercury intrusion porosimeter and associated computer software program known as “Porowin.” The procedure is documented in the Quantachrome Instruments PoreMaster Operation Manual. The PoreMaster determines both pore volume and pore diameter of a solid or powder by forced intrusion of a non-wetting liquid (mercury), which involves evacuation of the sample in a sample cell (penetrometer), filling the cell with mercury to surround the sample with mercury, applying pressure to the sample cell by: (i) compressed air (up to 50 psi maximum); and (ii) a hydraulic (oil) pressure generator (up to 60000 psi maximum). Intruded volume is measured by a change in the capacitance as mercury moves from outside the sample into its pores under applied pressure. The corresponding pore size diameter (d) at which the intrusion takes place is calculated directly from the so-called “Washburn Equation”: d=−(4γ(cosθ))/P where γ is the surface tension of liquid mercury, θ is the contact angle between mercury and the sample surface and P is the applied pressure.
  • Equipment used for pore volume measurements:
      • 1. Quantachrome Instruments PoreMaster 60.
      • 2. Analytical Balance capable of weighing to 0.0001 g.
      • 3. Desiccator.
  • Reagents used for measurements:
      • 1. High purity nitrogen.
      • 2. Triply distilled mercury.
      • 3. High pressure fluid (Dila AX, available from Shell Chemical Co.).
      • 4. Liquid nitrogen (for Hg vapor cold trap).
      • 5. Isopropanol or methanol for cleaning sample cells.
      • 6. Liquid detergent for cell cleaning.
  • Procedure:
  • The samples remain in sealed packages or as received in the dessicator until analysis. The vacuum pump is switched on, the mercury vapor cold trap is filled with liquid nitrogen, the compressed gas supply is regulated at 55 psi., and the instrument is turned on and allowed a warm up time of at least 30 minutes. The empty penetrometer cell is assembled as described in the instrument manual and its weight is recorded. The cell is installed in the low pressure station and “evacuation and fill only” is selected from the analysis menu, and the following settings are employed:
      • Fine Evacuation time: 1 min.
      • Fine Evacuation rate: 10
      • Coarse Evacuation time: 5 min.
  • The cell (filled with mercury) is then removed and weighed. The cell is then emptied into the mercury reservoir, and two tablets from each sample are placed in the cell and the cell is reassembled. The weight of the cell and sample are then recorded. The cell is then installed in the low-pressure station, the low-pressure option is selected from the menu, and the following parameters are set:
      • Mode: Low pressure
      • Fine evacuation rate: 10
      • Fine evacuation until: 200 μ Hg
      • Coarse evacuation time: 10 min.
      • Fill pressure: Contact +0.1
      • Maximum pressure: 50
      • Direction: Intrusion And Extrusion
      • Repeat: 0
      • Mercury contact angle; 140
      • Mercury surface tension: 480
  • Data acquisition is then begun. The pressure vs. cumulative volume-intruded 20 plot is displayed on the screen. After low-pressure analysis is complete, the cell is removed from the low-pressure station and reweighed. The space above the mercury is filled with hydraulic oil, and the cell is assembled and installed in the high-pressure cavity. The following settings are used:
      • Mode: Fixed rate
      • Motor speed: 5
      • Start pressure: 20
      • End pressure: 60 000
      • Direction: Intrusion and extrusion
      • Repeat: 0
      • Oil fill length: 5
      • Mercury contact angle: 140
      • Mercury surface tension: 480
  • Data acquisition is then begun and graphic plot pressure vs. intruded volume is displayed on the screen. After the high pressure run is complete, the low-and high-pressure data files of the same sample are merged.
  • The differences between the prior art and the present invention will be further understood with reference to FIGS. 1A and 1B. In FIG. 1A, Composition 1 is a Halls hard candy composition commercially available from Warner-Lambert Co., Morris Plains, N.J., and Composition 2 is dosage form according to the invention in which the confectionery composition is amorphous sugar glass. As show in FIG. 1A, when viewed under normal polarized light there are no distinguishing differences between Compositions 1 and 2. However, as shown in FIG. 1B, when viewed under polarized light at 90° filtering to the incident light, Composition 1 exhibits birefringence (i.e., refracted light) due to residual strain in the glass portion of the composition, whereas Composition 2 advantageously appears uniform without residual strain.
  • The dosage form of this invention is produced by molding. Several molding methods are known in the art, however it is preferred that the dosage form be made using the thermal setting molding method and apparatus described in copending U.S. application Ser. No. 09/966, 450, pages 57-63, or the thermal cycle molding method and apparatus described in copending U.S. application Ser. No. 09/966,497, pages 27-51, the disclosures of which are incorporated herein by reference.
  • In the thermal setting molding method, a starting material comprising the ingredients for the dosage form is injected into a molding chamber and molded into the desired shape. The starting material preferably comprises, in addition to the active ingredient and the confectionary composition, a thermal setting material at a temperature above the melting point of the thermal setting material but below the decomposition temperature of the active ingredient. The starting material is cooled and solidifies in the molding chamber into a shaped pellet (i.e., having the shape of the mold).
  • According to this method, the starting material must be in flowable form. For example, it may comprise solid particles suspended in a molten matrix, for example a polymer matrix. The starting material may be completely molten or in the form of a paste. The starting material may comprise an active ingredient dissolved in a molten material. Alternatively, the starting material may be made by dissolving a solid in a solvent, and the solvent is then evaporated from the starting material after it has been molded.
  • The thermal setting material may be any edible material that is flowable at a temperature between about 37 and about 250° C., and that is a solid or semi-solid at a temperature between about −10° C. and about 35° C. In certain embodiments, the thermal setting material may comprise all or a portion of the confectionary composition as well, as some of the same materials are useful for both. Preferred thermal setting materials include water-soluble polymers such as polyalkylene glycols, polyethylene oxides and derivatives, and sucrose esters; fats such as cocoa butter, hydrogenated vegetable oil such as palm kernel oil, cottonseed oil, sunflower oil, and soybean oil; free fatty acids and their salts; mono- di- and triglycerides, phospholipids, waxes such as camuba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; sugar in the form on an amorphous glass, sugar in a supersaturated solution,; low-moisture polymer solutions such as mixtures of gelatin and other hydrocolloids at water contents up to about 30% such as those used to make “gummi” confection forms. In a particularly preferred embodiment, the thermal setting material is a blend of fats and mono- and diglycerides.
  • In the thermal cycle molding method and apparatus of U.S. patent application Ser. No. 09/966,497, a thermal cycle molding module having the general configuration shown in FIG. 3 therein is employed. The thermal cycle molding module 200 comprises a rotor 202 around which a plurality of mold units 204 are disposed. The thermal cycle molding module includes a reservoir 206 (see FIG. 4) for holding flowable material to make the core. In addition, the thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units. FIGS. 55 and 56 of the '497 application depict the temperature control system 600.
  • In this embodiment, the mold units preferably comprise center mold assemblies 212 and upper mold assemblies 214 as shown in FIG. 26C of U.S. patent application Ser. No. 09/966,497, which mate to form mold cavities having the desired shape of the dosage form. As rotor 202 rotates, the opposing center and upper mold assemblies close. Flowable material comprising the ingredients of the dosage form, which is heated to a flowable state in reservoir 206, is injected into the resulting mold cavities. The temperature of the flowable material is then decreased, hardening the flowable material into dosage forms. The mold assemblies open and eject the dosage forms.
  • FIG. 2A is a photograph of a two-piece hard candy lozenge mold which may be used to prepare the dosage form of this invention. The mold in FIG. 2A is a 2-piece aluminum mold made up of first mold piece 2 and second mold piece 4. Mold pieces 2 and 4 have respective cavity portions 6 and 8 which form a cavity which has been polished to a mirror finish. Mold pieces 2 and 4 also have respective injection port portions 12 and 14 which define an injection port for injecting flowable material into the mold, as well as vent port portions 16 and 18 for venting air. FIG. 2B is a photograph of the mold depicted in FIG. 2A together with a lozenge dosage form 10 which has been removed from the mold.
  • This invention will be further illustrated by the following examples, which are not meant to limit the invention in any way.
  • EXAMPLE 1 Molded Hard Candy Dosage Form
  • A batch of molded hard candy lozenges was prepared in the following manner:
  • Hard Candy Pre-cook Formulation:
  • The following ingredients were used to prepare the formulation:
    Ingredient % mg/tab gms/batch
    Corn Syrup (42 DE) 45.35 170.06 498.85
    Sugar (dry granular) 45.35 170.06 498.85
    Purified Water USP 9.05 33.93 99.60
    FD&C Red #40 0.05 0.20 0.50
    Flavor 0.20 0.75 2.20
    TOTAL 100.00 375.00 1100.0
  • The corn syrup was weighed into a tared non-stick 2-quart saucepan. Purified water was then added to the same pan and the mixture was warmed over low heat with stirring until homogeneous. To the diluted corn syrup, dry granular sugar was added and stirred to form a wet slurry.
  • Cook Step:
  • The sugar, water, corn syrup mixture was heated rapidly on a gas-fired stove over high heat with gentle stirring until the mixture appeared clear and began to boil. Heating continued until the mixture reached a temperature of 120° C. at which point the heat was reduced to a medium flame. Heating was continued over a medium flame until 140° C. was reached at which point the color was added to the batch and stirred in until uniformly distributed. When the temperature reached 145° C., the batch was removed from the stove and the flavor was blended into the batch. Subsequently, the batch was allowed to cool slightly without mixing so that air bubbles would dissipate.
  • Molding Step:
  • While maintaining the batch in a fluid state by occasional heating, the molten candy base was injected into a two piece metal mold held together by thumbscrews (as shown in FIGS. 2A and 2B). The mold, constructed from aluminum, had an injection port and a vent port that allowed excess candy mass to exit the mold. The fill cavity, in the shape of the desired lozenge piece, was polished to provide a molded dosage form having a smooth shiny surface. The injection device, a 10 cc plastic syringe having a cut off tip, was used to transfer candy base from the cooked batch and inject the candy base into the injection port of the molding apparatus. Once filled, the mold was allowed to cool at room temperature for about 2 minutes before opening. Upon opening, the molded dosage form was removed and any excess hard candy web from the fill and vent ports was snapped off.
  • EXAMPLE 2 Hard Candy Dosage Form
  • A dosage form according to the invention is made following the procedure stated in Example 1, except the hard candy pre-cook formation is as follows:
    Ingredient % mg/tab gms/batch
    Corn Syrup (42 DE) 44.99 170.06 498.85
    Sugar (dry granular) 44.99 170.06 498.85
    Purified Water USP 8.98 33.93 99.60
    FD&C Red #40 0.05 0.20 0.50
    Flavor 0.20 0.75 2.20
    Benzydamine 0.79 3.00 8.80
    TOTAL 100.00 378.00 1108.8

    Here, the active ingredient, benzydamine, is added along with the flavor after the batch is removed from the stove.
  • EXAMPLE 3 Hard Candy Menthol Lozenge Dosage Form
  • A commercial scale batch of hard candy menthol dosage forms according to the invention is made using thermal cycle molding and the formulation set forth below:
  • Hard Candy Pre-cook Formulation:
  • The following ingredients including menthol as the active ingredient, are used to prepare the formulation:
    Theory
    Ingredient Supplier Percent Mg/tab Kg/batch
    Sucrose Florida Crystals, FL  46.91 1407..3 234.6
    (dry granular)
    Corn Syrup Archer Daniel Midland,  38.44 1153.2 192.2
    42 DE CA
    Menthol A1 Menthol Century  0.40*  12.0*  2.00*
    Int'l, CA
    Purified Water  14.0  420.0  70.0
    Flavor  0.20   6.00  1.00
    Color  0.05   1.5  0.25
    TOTAL 100.0 3000 500.0

    *Includes a 17% overage for loss during processing.
  • Sucrose, corn syrup and water from the pre-cook formulation is vacuum cooked by a batch method. Other suitable methods include semicontinuous, and continuous vacuum cooking. Confectionery vacuum cookers are manufactured by APV Baker (Peterborough, UK), Kloeckner-Hansel GmbH (Cape Coral, Fla.), and Hosokawa Ter Braak B. V. (Rotterdam, Netherlands).
  • Sugar and water are added to the syrup cooking pan of the vacuum cooker and heated to about 110° C. to completely dissolve the sugar crystals. Subsequently, the corn syrup is added and the mixture is cooked to about 138° C. and then discharged to the lower pan under vacuum (620 mm). In the lower pan, color, flavor, and menthol are added and mixed into the batch.
  • While still fluid, the cooked hard candy batch is transferred to heated supply tanks or reservoirs, such as those shown as 206 in FIG. 4 of copending U.S. application Ser. No. 09/966,497. The cooked hard candy batch is maintained within the reservoirs at about 120° C. without stirring. The reservoirs 206 are covered and pressurized to about 150 psi or sufficient pressure to allow the fluid hard candy mass to flow to a thermal cycle molding module as follows.
  • The dosage forms are then made in a thermal cycle molding module thermal cycle molding module having the specific configuration shown in FIG. 26A of copending U.S. application Ser. No. 09/966,497. The thermal cycle molding module comprises center mold assemblies 212 and upper mold assemblies 214 as shown in FIG. 26C, which mate to form mold cavities having the shape of a hard candy. As rotor 202 rotates, the opposing center and upper mold assemblies close. The fluid, cooked hard candy batch is injected into the resulting mold cavities.
  • The mold assemblies are thermally cycled between about 120° C. and about 90° C. and receive the hot cooked hard candy batch material when its cycle is in the high temperature range. As the hot material fills the mold cavity, the mold temperature is cycled to the low temperature range (i.e. 60-90° C.) and cools the material to a temperature where it is sufficiently solid that it no longer flows under its own weight. Once set (i.e., for 1-60 seconds), the mold assemblies open and the molded dosage form is ejected from the thermal cycle molding module and conveyed to a tray to cool and completely harden.
  • Once cooled to room temperature (22° C.), a batch of molded hard candy lozenge dosage forms is ready to be transferred in bulk to a packaging line.
  • EXAMPLE 4 Surface Gloss Comparisons
  • Commercially available molded lozenges were tested for surface gloss using an instrument available from TriCor Systems Inc. (Elgin, Ill.) under the tradename, “TRI-COR MODEL 805A/806H SURFACE ANALYSIS SYSTEM” and generally in accordance with the procedure described in “TriCor Systems WGLOSS 3.4 Model 805A/806H Surface Analysis System Reference Manual” (1996), which is incorporated by reference herein, except as modified below,
  • This instrument utilized a CCD camera detector, employed a flat diffuse light source, compared tablet samples to a reference standard, and determined average gloss values at a 60 degree incident angle. During its operation, the instrument generated a gray-scale image, wherein the occurrence of brighter pixels indicated the presence of more gloss at that given location.
  • The instrument also incorporated software that utilized a grouping method to quantify gloss, i.e., pixels with similar brightness were grouped together for averaging purposes.
  • The “percent full scale” or “percent ideal” setting (also referred to as the “percent sample group” setting), was specified by the user to designate the portion of the brightest pixels above the threshold that will be considered as one group and averaged within that group. As used herein, “threshold” is defined as the maximum gloss value that will not be included in the average gloss value calculation. Thus, the background, or the non-glossy areas of a sample were excluded from the average gloss value calculations. The method disclosed in K. Fegley and C. Vesey, “The Effect of Tablet Shape on the Perception of High Gloss Film Coating Systems”, which is available at www.colorcon.com as of 18 Mar., 2002 and incorporated by reference herein, was used to minimize the effects resulting from different dosage form shapes, and to report a metric that was comparable across the industry. (The 50% sample group setting was selected as the setting which best approximated analogous data from tablet surface roughness measurements.)
  • After initially calibrating the instrument using a calibration reference plate (190-228; 294 degree standard; no mask, rotation 0, depth 0), a standard surface gloss measurement was then created using gel-coated caplets available from McNEIL-PPC, Inc. under the tradename, “EXTRA STRENGTH TYLENOL GELCAPS.” The average gloss value for a sample of 112 of such gel-coated caplets was then determined, while employing the 25 mm full view mask (190-280), and configuring the instrument to the following settings:
      • Rotation: 0
      • Depth: 0.25 inches
      • Gloss Threshold: 95
      • % Full Scale (% ideal): 50%
      • Index of Refraction: 1.57
        The average surface gloss value for the reference standard was determined to be 269.
  • Each face of each sample molded lozenge was then independently tested in accordance with the same procedure. For the deposited samples, the “free-formed” face was designated as “Face 1.” The opposing face was designated as “Face 2”. A 31 by 31 pixel area (corresponding to an area on the sample of about 3.1 mm×3.1 mm, or 9.61 square millimeters) was chosen to minimize contribution from air bubbles. HALLS PLUS lozenges available from Warner-Lambert Company, Morris Plains, N.J. were selected as exemplary of lozenges manufactured by a conventional uniplasting process (Sample A). Cepacol® Sore Throat Lozenges, available from J. B. Williams Co., Glen Rock, N.J., and JOLLY RANCHER HARD CANDY available from Hershey Foods Corp, Hershey, Pa. were selected as exemplary of lozenges manufactured by conventional depositing methods (Samples B and C, respectively). Injection molded lozenges made according to the method of Example 1 were designated as Sample D. The results obtained were as follows:
    Gloss -
    Manufacturing Gloss - Gloss - Difference
    Sample Method Face 1 Face 2 (gloss units)
    A (Halls Plus ®) Uniplast ™ 225 210 15
    punch molded
    B (Cepacol ®) Deposited 282 261 21
    C (Jolly Rancher ®) Deposited 296 256 40
    D (Example 1) Injection 291 297 6
    Molded
  • The results indicate that lozenge-type dosage forms according to the invention have a small difference in surface gloss between the two faces. In contrast, commercially available lozenges molded by depositing had surface glosses on their free-formed faces at least about 21 gloss units higher than the surface gloss on their molded faces. Lozenges made by the Uniplast punch method also showed less difference in surface gloss between their 2 major faces than those prepared by depositing.
  • EXAMPLE 5 Weight Variation of Comparative Products
  • Variation in piece weight of various commercially available confectionery forms, representative of conventional confectionery processing methods was measured by the following method. The weight of 30 individual pieces of each form was determined to the nearest 0.1 milligram using an analytical balance. From the 30 individual piece weights for each sample, a mean, sample standard deviation, and relative standard deviation (% RSD) were calculated. Note the relative standard deviation is the standard deviation expressed as a percentage of the mean, as known in the art.
    Relative Standard
    Mean Piece Standard Deviation in Deviation in piece
    Product Supplier Weight (g) piece weight (g) Weight (%)
    Jolly Rancher ® Hershey Foods Corp, 5.9108 0.1972 3.34
    Hard Candy Hershey, PA
    Tootsie Roll ® Tootsie Roll Industries, 6.5572 0.1248 1.90
    Inc, Chicago, IL
    Hershey ®'s Hershey Foods Corp. 4.6323 0.1523 3.29
    Kisses ® Hershey, PA
    Halls ® Cough Warner-Lambert 3.7859 0.0652 1.72
    Suppressant Company, Morris Plains,
    Drops NJ
    Werther ®'s Storck USA L.P., 5.1829 0.1294 2.50
    Original Hard Chicago, IL
    Candy
    Kraft ® Caramels Nabisco Inc., East 7.9660 0.3844 4.83
    Hanover NJ
  • EXAMPLE 6 Visualization and Quantification of Strain in Hard Candy Glass
  • Samples of hard candy glass were viewed and photographed under plane polarized light to quantify the relative strain in the candy glass. Sample A was a Halls Plus® lozenge commercially available from Warner-Lambert Co., Morris Plains, N.J. Sample B was an injection molded lozenge made according to Example 1 herein. Sample C was a Chloraseptic lozenge commercially available from Prestige Brands International, Inc., Bonita Springs, Fla. Samples A and C are exemplary of Uniplast™ punch molded hard candy glass products. Typically, injection molded and deposited hard candy show no intrinsic strain whereas punch or roller molded hard candy retain residual strain that is visible when viewed under a strain viewer. The equipment used was as follows:
      • 1) Camera—Scalar Portable Digital Microscope DG-1 fitted with the 1X lens with a C-mount adapter.
      • 2) Strain Viewer—The strain viewer used was fabricated using:
        • Portable light box containing an 8 watt florescent lamp (Apollo—model LB 101, Ronkonkoma, N.Y. 11779).
        • Two 5″×3″ pieces of linear polarizing filters. Available from the 3M Company e.g., HN32—Neutral linear polarizer or other suitable for stress analysis.
  • As depicted in FIGS. 3A and 3B, a first filter 300 was secured to the middle of a light box 302 with cellophane tape and a second filter 304 was held by hand, parallel above the first filter 302. Samples (306 and 308) being analyzed were placed on top of the first filter 300 but beneath the second filter 304. Light transmission was regulated by rotating the second filter 304 while maintaining its parallel position above the first filter 300, as shown in FIG. 3B.
  • Alternatively, strain viewers are commercially available from: Strainoptic Technologies, Inc., 108 W. Montgomery Ave., North Wales, Pa. 19454, or from Sharples Stress Engineers, LTD, Unit 29 Old Mill Industrial Estate, School Lane, PR5 6SY Lancashire, UK.
  • Photographs of the samples were recorded using a digital camera. The pictures were taken through the second filter at both the maximum light transmission angle and the minimum light transmission angle (maximum extinction) with respect to the sample image (not the filter).
  • FIGS. 4A and 4B depict typical photographic images for a punch molded hard candy (Sample A) and an injection molded or deposited hard candy (Sample B) when viewed as described at maximum and minimum light transmission through a pair of polarizing filters.
  • Subsequently, image analysis software (Sigma Scan Pro 5 available from SPSS, Inc.) was used to quantitatively characterize the observed strain in the hard candy glass. Equivalent areas of the color images (free of bubble defects and cracks) were converted into gray scale and displayed as a histogram of pixel elements ranging in value from 0 (black) to 255 (white). For purposes of resolution, sample illumination and digital image exposure is adjusted to maximize the peak separation between the transmission and extinction states.
  • As seen in FIGS. 5 and 6, a converted image appears as a peak-like distribution of gray scale pixels. Moreover, the peak maximum for a given sample differs when the polarization filters are at maximum light transmission (0°) versus maximum light extinction (˜90°). Drop roll or punch molded hard candy samples, such as the Chloraceptic® Lozenge (Sample C) depicted in FIG. 5, brighten as polarization reaches the point of maximum extinction and their gray scale peaks shift to higher values. Conversely, in the case of injection molded and deposited hard candy samples, their images darken and their gray scale peaks shift to smaller values as the polarized light reaches high extinction levels.
  • Although this invention has been illustrated by reference to specific embodiments, it will be apparent to those skilled in the art that various changes and modifications may be made which clearly fall within the scope of this invention.

Claims (23)

1. A dosage form comprising at least one active ingredient and a confectionery composition wherein the relative standard deviation of the weight of the dosage form is less than 1%, and the dosage form has at least one face.
2. A dosage form comprising at least one active ingredient and a confectionery composition wherein the dosage form has at least one face, does not have a free formed surface, and has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
3. The dosage form of claim 2, in which the relative standard deviation of the weight of the dosage form is less than 1%.
4. The dosage form of claim 1, in which the relative standard deviation of the weight of the dosage form is less than 0.5%.
5. The dosage form of claim 1, in which the confectionery composition comprises at least one component selected from the group consisting of fat, amorphous sugar glass and fondant.
6. The dosage form of claim 1, in which the confectionery composition does not contain a gelatin based composition.
7. The dosage form of claim 1, in which the confectionery composition does not contain a gel based composition.
8. The dosage form of claim 1, in which the confectionery composition comprises an amorphous sugar glass component and the dosage form does not have a free formed surface.
9. The dosage form of claim 1, in which all the faces of the dosage form have a surface gloss of about 200-300 gloss units.
10. The dosage form of claim 1, in which the dosage form has two or more faces, and the difference in surface gloss between any two faces is not more than about 20 gloss units.
11. The dosage form of claim 10 in which the difference in surface gloss between any two faces is not more than about 15 gloss units.
12. The dosage form of claim 10 in which the difference in surface gloss between any two faces is not more than about 10 gloss units.
13. The dosage form of claim 1 in which the dosage form has a mean polarized light transmission at the angle of maximum extinction which is not greater than the mean polarized light transmission of the dosage form at the angle of maximum transmission.
14. The dosage form of claim 1, in which the dosage form has a mean polarized light transmission between about 0 to 40 grayscale units at the angle of maximum extinction.
15. The dosage form of claim 1 in which the confectionery composition comprises an amorphous sugar glass component and the dosage form does not have a free formed surface.
16. The dosage form of claim 1 in which the active ingredient is a pharmaceutically active ingredient.
17. The dosage form of claim 1, in which the dosage form comprises particles which comprise the active ingredient.
18. The dosage form of claim 17, in which the particles have an average particle size of about 50 to about 2000 microns.
19. The dosage form of claim 17, in which at least a portion of the particles are coated particles.
20. The dosage form of claim, in which the dosage form is a unitary object.
21. The dosage form of claim 1, in which the dosage form does not contain any seams on its surface.
22. The dosage form of claim 1 in which the confectionery composition comprises an amorphous sugar glass component.
23. The dosage form of claim 1, in which the dosage form is substantially free of pores having a diameter of 0.5 to 5.0 microns.
US10/476,503 2001-09-28 2002-09-28 Dosage form containing a confectionery composition Abandoned US20050019376A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/476,503 US20050019376A1 (en) 2001-09-28 2002-09-28 Dosage form containing a confectionery composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/966,939 US6837696B2 (en) 2001-09-28 2001-09-28 Apparatus for manufacturing dosage forms
US10/476,503 US20050019376A1 (en) 2001-09-28 2002-09-28 Dosage form containing a confectionery composition
PCT/US2002/031115 WO2003026614A1 (en) 2001-09-28 2002-09-28 Dosage form containing a confectionery composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/966,939 Continuation-In-Part US6837696B2 (en) 2001-09-28 2001-09-28 Apparatus for manufacturing dosage forms

Publications (1)

Publication Number Publication Date
US20050019376A1 true US20050019376A1 (en) 2005-01-27

Family

ID=25512088

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/966,939 Expired - Lifetime US6837696B2 (en) 2001-09-28 2001-09-28 Apparatus for manufacturing dosage forms
US10/476,503 Abandoned US20050019376A1 (en) 2001-09-28 2002-09-28 Dosage form containing a confectionery composition
US12/360,579 Abandoned US20090186082A1 (en) 2001-09-28 2009-01-27 Method of manufacturing modified release dosage forms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/966,939 Expired - Lifetime US6837696B2 (en) 2001-09-28 2001-09-28 Apparatus for manufacturing dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/360,579 Abandoned US20090186082A1 (en) 2001-09-28 2009-01-27 Method of manufacturing modified release dosage forms

Country Status (17)

Country Link
US (3) US6837696B2 (en)
EP (1) EP1429915B1 (en)
JP (1) JP2005504639A (en)
KR (1) KR100861670B1 (en)
CN (2) CN100488763C (en)
AT (1) ATE420762T1 (en)
AU (1) AU2002337711B2 (en)
CA (1) CA2462008C (en)
DE (1) DE60230886D1 (en)
ES (1) ES2319971T3 (en)
HU (1) HUP0401653A2 (en)
MX (1) MXPA04002971A (en)
NO (1) NO20041716L (en)
NZ (1) NZ532095A (en)
PL (1) PL369169A1 (en)
WO (1) WO2003028990A1 (en)
ZA (2) ZA200403167B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237855A1 (en) * 2006-04-05 2007-10-11 Cadbury Adams Usa Llc Calcium phosphate complex in acid containing confectionery
US20090018639A1 (en) * 2007-07-11 2009-01-15 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20100255084A1 (en) * 2009-04-06 2010-10-07 Yoel Ovil Medicinal melting capsules for oral mucosal absorption
US20100255088A1 (en) * 2009-04-06 2010-10-07 Yoel Ovil Method for delivering a combination of resveratrol and aspirin for use in treatment and prevention of vascular disease
US20100255086A1 (en) * 2009-04-06 2010-10-07 Yoel Ovil Method for oral mucosal absorption of acetyl salycylic acid
US20100297203A1 (en) * 2006-04-05 2010-11-25 Cadbury Adams Usa, Llc Impact of calcium phosphate complex on dental caries
US8133476B2 (en) 2006-04-05 2012-03-13 Cadbury Adams Usa Llc Calcium phosphate complex and salts in oral delivery systems
WO2018217241A1 (en) 2017-05-22 2018-11-29 Johnson & Johnson Consumer Inc. Lozenge dosage form

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US7217381B2 (en) * 2001-09-28 2007-05-15 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
EP1438028A1 (en) * 2001-09-28 2004-07-21 McNEIL-PPC, INC. Modified release dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
ITMO20030122A1 (en) * 2003-04-30 2004-11-01 Sacmi APPARATUS AND METHOD FOR AWAYING OBJECTS FROM TRAINING VEHICLES.
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
GB0322358D0 (en) * 2003-09-24 2003-10-22 Bioprogress Technology Ltd Improvements in powder compaction and enrobing
ITMO20030289A1 (en) * 2003-10-23 2005-04-24 Sacmi EQUIPMENT, METHOD AND ARTICLE.
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US7178562B2 (en) * 2004-04-08 2007-02-20 Graham Packaging Pet Technologies Inc. Pellet transfer apparatus and method
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
EP1944008A3 (en) * 2004-09-24 2008-07-23 BioProgress Technology Limited Additional improvements in powder compaction and enrobing
CN101065091A (en) * 2004-09-24 2007-10-31 生物进展技术有限公司 Additional improvements in powder compaction and enrobing
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) * 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
KR100597182B1 (en) 2004-10-29 2006-07-05 한영수 Forming apparatus of cones strengtrening for pelvic floor muscles
US7404708B2 (en) * 2004-12-07 2008-07-29 Mcneil-Ppc, Inc. System and process for providing at least one opening in dosage forms
US7530804B2 (en) * 2004-12-07 2009-05-12 Mcneil-Ppc, Inc. System and process for providing at least one opening in dosage forms
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
US8211078B2 (en) 2005-02-17 2012-07-03 The Procter And Gamble Company Sanitary napkins capable of taking complex three-dimensional shape in use
US9579238B2 (en) 2005-02-17 2017-02-28 The Procter & Gamble Company Sanitary napkins capable of taking complex three-dimensional shape in use
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20070048366A1 (en) * 2005-08-26 2007-03-01 Jen-Chi Chen Gelatin-based coatings having improved durability
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
JP4841564B2 (en) * 2005-12-06 2011-12-21 旭化成ケミカルズ株式会社 Tablet production method by high-speed direct tableting
DE102005061787A1 (en) * 2005-12-23 2007-06-28 Fette Gmbh Device for generating a negative pressure in the sealed space of a tablet press and / or an insulator
US7630787B2 (en) * 2006-04-19 2009-12-08 Husky Injection Molding Systems Ltd System for integrating insert with molded article
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
FI20070521L (en) * 2006-11-10 2008-05-11 Atacama Labs Oy Grains, tablets and granulation process
FI20060990A0 (en) * 2006-11-10 2006-11-10 Iprbox Oy Grains, tablets and granulation method
EP1952696A1 (en) * 2007-02-01 2008-08-06 Nestec S.A. A method and apparatus for making centre-filled shaped food products
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
CN101646421A (en) * 2007-04-26 2010-02-10 卫材R&D管理有限公司 The preparation method of tablet
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP5098535B2 (en) * 2007-09-21 2012-12-12 東洋製罐株式会社 Molten resin feeder
US7867418B2 (en) * 2007-09-24 2011-01-11 Mars, Incorporated Tool and apparatus for forming a moldable material
RU2493830C2 (en) 2008-01-25 2013-09-27 Грюненталь Гмбх Drug form
BRPI0912014A2 (en) 2008-05-09 2019-03-06 Grünenthal GmbH A process for preparing an intermediate powder formulation and a final solid dosage form using a spray freeze step
EP2291233B1 (en) * 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
US8328966B1 (en) * 2008-09-11 2012-12-11 The United States Of America As Represented By The Secretary Of The Navy Method for making miniature explosive powder charges
US8382921B1 (en) * 2008-09-11 2013-02-26 The United States Of America As Represented By The Secretary Of The Navy Apparatus for making miniature explosive powder charges
IT1394597B1 (en) * 2008-11-05 2012-07-05 Politi DRY GRANULATION IN GAS FLOW.
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
BR112012001547A2 (en) 2009-07-22 2016-03-08 Gruenenthal Gmbh hot melt extruded pharmaceutical dosage form
JP2012533585A (en) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant dosage forms for oxidation-sensitive opioids
US8343533B2 (en) 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
BR112014002022A2 (en) 2011-07-29 2017-02-21 Gruenenthal Gmbh tamper-resistant tablet providing immediate drug release
CN103857386A (en) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 Tamper-resistant tablet providing immediate drug release
ES2569045T3 (en) * 2011-08-24 2016-05-06 Unilever N.V. Delivery particles of a benefit agent comprising non-ionic polysaccharides
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2013183497A1 (en) 2012-06-05 2013-12-12 武田薬品工業株式会社 Dry-coated tablet
US8399011B1 (en) * 2012-08-10 2013-03-19 Magnifica Inc. Oral particle compositions containing a core and an acid-soluble coat
MX2015016254A (en) 2013-05-29 2016-04-20 Gruenenthal Gmbh Tamper resistant dosage form with bimodal release profile.
BR112015026549A2 (en) 2013-05-29 2017-07-25 Gruenenthal Gmbh tamper-proof dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US20150093439A1 (en) * 2013-09-27 2015-04-02 Mcneil-Ppc, Inc. Compression coated pulsatile release compositions
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
JP6075278B2 (en) * 2013-12-05 2017-02-08 株式会社デンソー Press machine
CA2936216C (en) 2014-01-10 2021-10-26 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
MX2016014738A (en) 2014-05-12 2017-03-06 Gruenenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol.
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
KR20160126217A (en) 2015-04-23 2016-11-02 주식회사 진명 에프 엠 씨 Apparatus For Supplying Container
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
TWI580310B (en) * 2015-08-14 2017-04-21 Bottle-Top Dev Co Microwave heating system
CA2996041A1 (en) 2015-08-21 2017-03-02 Aprecia Pharmaceuticals LLC Three-dimensional printing system and equipment assembly
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
ITUB20154653A1 (en) 2015-10-14 2017-04-14 Sacmi Apparatus and method for processing doses.
PL3222414T3 (en) * 2016-03-24 2020-04-30 Korsch Ag Rotation press with stamps with at least two stamp tips at staggered heights for carrying out multiple pressing processes during a rotation
CN106166849A (en) * 2016-08-24 2016-11-30 海宁艾迪欧动物保健品科技有限公司 A kind of Chinese crude drug cake of press device of automatic charging
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
CN107028901A (en) * 2017-03-29 2017-08-11 陈永雷 A kind of medicine lozenge, functional food lozenge, health food lozenge regional compartmentalization prepare method
CN107041845B (en) * 2017-05-05 2023-05-23 杨超翔 Child drug delivery device and method
CN108158816B (en) * 2018-01-18 2021-01-19 广东省惠州市中药厂有限公司 Rhizome medicinal material extraction and granulation equipment and extraction method
GB2578272B (en) * 2018-07-10 2023-03-29 Innopharma Res Limited Apparatus and method for the production of solid dosage forms
CN116115554A (en) 2018-10-15 2023-05-16 阿普雷奇亚制药有限责任公司 Method and system for forming dosage forms in packages
US11413839B2 (en) * 2018-12-14 2022-08-16 Natoli Engineering Company, Inc. Device to level a feeder platform
DE102019210354A1 (en) * 2019-07-12 2021-01-14 Theegarten-Pactec Gmbh & Co. Kg Rotary head with rotating work stations
IT202000012685A1 (en) * 2020-05-28 2021-11-28 Perfetti Van Melle Spa METHOD FOR MAKING A COMPRESSED PRODUCT
US20220068457A1 (en) * 2020-08-28 2022-03-03 Omnicell, Inc. Systems and methods for parallel preparation processing
CN112590291B (en) * 2020-12-04 2022-07-22 重庆医药高等专科学校 Tabletting device for pharmacy
CN113002046B (en) * 2021-03-03 2021-12-14 林美珊 Spiral extrusion type solid-liquid separator
CN115581262A (en) * 2022-09-08 2023-01-10 江西诺泰生物科技有限公司 Automatic forming device for sports nutritious food

Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86973A (en) * 1869-02-16 Improvement in tarn-guide and clearer
US124183A (en) * 1872-02-27 Improvement in packings for engines
US2307371A (en) * 1941-08-13 1943-01-05 Ray O Vac Co Molding process
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3085942A (en) * 1960-12-28 1963-04-16 Hoffmann La Roche Antitussive compositions and preparation
US3146169A (en) * 1960-01-21 1964-08-25 Burroughs Wellcome Co Pharmaceutical formulations and their manufacture
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
US3726622A (en) * 1971-08-20 1973-04-10 Wolverine Pentronix Compacting apparatus
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
US4097606A (en) * 1975-10-08 1978-06-27 Bristol-Myers Company APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same
US4139589A (en) * 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US4139627A (en) * 1977-10-06 1979-02-13 Beecham Inc. Anesthetic lozenges
US4230693A (en) * 1975-04-21 1980-10-28 Armour-Dial, Inc. Antacid tablets and processes for their preparation
US4271206A (en) * 1979-10-26 1981-06-02 General Foods Corporation Gasified candy having a predetermined shape
US4273793A (en) * 1979-10-26 1981-06-16 General Foods Corporation Apparatus and process for the preparation of gasified confectionaries by pressurized injection molding
US4362757A (en) * 1980-10-22 1982-12-07 Amstar Corporation Crystallized, readily water dispersible sugar product containing heat sensitive, acidic or high invert sugar substances
US4371516A (en) * 1976-10-06 1983-02-01 John Wyeth & Brother Limited Articles for carrying chemicals
US4372942A (en) * 1981-08-13 1983-02-08 Beecham Inc. Candy base and liquid center hard candy made therefrom
US4425332A (en) * 1978-09-21 1984-01-10 Beecham Group Limited Antacid composition
US4517205A (en) * 1983-01-03 1985-05-14 Nabisco Brands, Inc. Co-deposited two-component hard candy
US4661521A (en) * 1984-04-30 1987-04-28 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4686212A (en) * 1985-08-13 1987-08-11 Pharmacontrol Corp. Stable sodium aspirin tablet compositions
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4762719A (en) * 1986-08-07 1988-08-09 Mark Forester Powder filled cough product
US4781714A (en) * 1983-11-02 1988-11-01 Alza Corporation Dispenser for delivering thermo-responsive composition
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4882167A (en) * 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4894236A (en) * 1988-01-12 1990-01-16 Choong-Gook Jang Direct compression tablet binders for acetaminophen
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
US4980169A (en) * 1990-05-03 1990-12-25 Warner-Lambert Company Flavor enhancing and increasing efficacy of cough drops
US4983394A (en) * 1990-05-03 1991-01-08 Warner-Lambert Company Flavor enhancing and medicinal taste masking agent
US5002970A (en) * 1981-07-31 1991-03-26 Eby Iii George A Flavor masked ionizable zinc compositions for oral absorption
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US5200191A (en) * 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
US5213808A (en) * 1989-09-22 1993-05-25 Buhk Meditec A/A Controlled release article with pulsatile release
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5228916A (en) * 1990-11-05 1993-07-20 Mcneil-Ppc, Inc. Apparatus for creating a gelatin coating
US5229164A (en) * 1985-12-19 1993-07-20 Capsoid Pharma Gmbh Process for producing individually dosed administration forms
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5368863A (en) * 1990-01-24 1994-11-29 Alza Corporation Long-term delivery device with early startup
US5391378A (en) * 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
US5405642A (en) * 1991-02-27 1995-04-11 Janssen Pharmaceutica N.V. Method of highlighting intagliations in tablets
US5415868A (en) * 1993-06-09 1995-05-16 L. Perrigo Company Caplets with gelatin cover and process for making same
US5436026A (en) * 1990-11-05 1995-07-25 Mcneil-Ppc, Inc. Discharge and transfer system for apparatus for gelatin coating tablets
US5456920A (en) * 1993-02-10 1995-10-10 Takeda Chemical Industries, Ltd. Uncoated tablets and method of producing the same
US5464631A (en) * 1990-06-27 1995-11-07 Warner-Lambert Company Encapsulated dosage forms
US5489436A (en) * 1991-06-14 1996-02-06 Mcneil-Ppc, Inc. Taste mask coatings for preparation of chewable pharmaceutical tablets
US5511361A (en) * 1992-08-07 1996-04-30 Warner-Lambert Company Encapsulation method
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5578336A (en) * 1995-06-07 1996-11-26 Monte; Woodrow C. Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making
US5614207A (en) * 1995-06-30 1997-03-25 Mcneil-Ppc, Inc. Dry mouth lozenge
US5681584A (en) * 1993-04-23 1997-10-28 Ciba-Geigy Corporation Controlled release drug delivery device
US5711961A (en) * 1994-07-26 1998-01-27 Apr Applied Pharma Research S.A. Pharmaceutical compositions based on chewing gum and a method for the preparation thereof
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
US5824338A (en) * 1996-08-19 1998-10-20 L. Perrigo Company Caplet and gelatin covering therefor
US5830501A (en) * 1991-12-06 1998-11-03 Alza Corporation Dosage form comprising hydrophilic polymer
US5830502A (en) * 1994-10-28 1998-11-03 Alza Corporation Injection-molded dosage form
US5853760A (en) * 1993-12-04 1998-12-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Device for the controlled release of active substances
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US6001391A (en) * 1997-03-12 1999-12-14 Basf Aktiengesellschaft Process for producing solid drug forms having at least two phases
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6103257A (en) * 1998-07-17 2000-08-15 Num-Pop, Inc. System for delivering pharmaceuticals to the buccal mucosa
US6117479A (en) * 1995-05-09 2000-09-12 Phoqus Limited Electrostatic coating
US6149939A (en) * 1997-05-09 2000-11-21 Strumor; Mathew A. Healthful dissolvable oral tablets, and mini-bars
US6200590B1 (en) * 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US20010001280A1 (en) * 1998-09-09 2001-05-17 Liang-Chang Dong Dosage form comprising liquid formulation
US6248361B1 (en) * 1999-02-26 2001-06-19 Integ, Ltd. Water-soluble folic acid compositions
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
US6350398B1 (en) * 1998-09-03 2002-02-26 Basf Aktiengesellschaft Process for producing coated solid dosage forms
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US599865A (en) * 1898-03-01 Emanuel l
US2386173A (en) * 1943-05-13 1945-10-02 American Viscose Corp Apparatus for the production of artificial filaments
GB759081A (en) 1954-04-15 1956-10-10 John Holroyd And Company Ltd Improvements relating to machines for the production of coated tablets and the like
US2849965A (en) * 1954-04-15 1958-09-02 John Holroyd & Company Ltd Machines for use in the production of coated tablets and the like
US2946298A (en) * 1957-11-13 1960-07-26 Arthur Colton Company Compression coating tablet press
DE1155348B (en) 1958-11-13 1963-10-03 Tatra Np Pneumatic actuation device for switching a step change gear, especially for motor vehicles
GB936386A (en) 1959-01-16 1963-09-11 Wellcome Found Pellets for supplying biologically active substances to ruminants
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
GB994742A (en) 1960-09-09 1965-06-10 Wellcome Found Pharmaceutical tablets containing anthelmintics, and the manufacture thereof
BE636865A (en) * 1962-08-31
GB1144915A (en) 1966-11-24 1969-03-12 Armour Pharma Improvements in or relating to pastille formulations
CH569482A5 (en) 1970-12-23 1975-11-28 Boehringer Sohn Ingelheim
DE2157465C3 (en) * 1971-11-19 1975-04-24 Werner & Pfleiderer, 7000 Stuttgart Filling device for a hydraulic block press
SE414386B (en) 1976-03-10 1980-07-28 Aco Laekemedel Ab VIEW TO PREPARE AND AT THE SAME PACKAGE PHARMACEUTICAL DOSAGE UNITS
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
NL7906689A (en) * 1979-09-06 1981-03-10 Dawsonville Corp Nv TATTOO.
US4473526A (en) * 1980-01-23 1984-09-25 Eugen Buhler Method of manufacturing dry-pressed molded articles
US4292017A (en) * 1980-07-09 1981-09-29 Doepel Wallace A Apparatus for compressing tablets
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
DE3144678A1 (en) * 1981-11-10 1983-05-19 Eugen Dipl.-Ing. 8871 Burtenbach Bühler METHOD AND DEVICE FOR THE PRODUCTION OF MOLDINGS FROM A GIANT CAPABILITY
JPS58152813A (en) 1982-03-08 1983-09-10 Sumitomo Chem Co Ltd Tablet having clear carved seal and its preparation
US4516335A (en) * 1982-04-09 1985-05-14 Sanyo Electric Co., Ltd. Clothes dryer
DK151608C (en) * 1982-08-13 1988-06-20 Benzon As Alfred PROCEDURE FOR PREPARING A PHARMACEUTICAL PERORAL POLYDEPOT PREPARATION WITH CONTROLLED RELEASE
DE3404108A1 (en) * 1984-02-07 1985-08-14 Kilian & Co GmbH, 5000 Köln TABLET PRESS
US4518335A (en) 1984-03-14 1985-05-21 Allied Corporation Dilatant mold and dilatant molding apparatus
JPS60217106A (en) * 1984-04-12 1985-10-30 高橋 信之 Inorganic-powder freezing molding method
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
GB8517073D0 (en) * 1985-07-05 1985-08-14 Hepworth Iron Co Ltd Pipe pipe couplings &c
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE3610878A1 (en) 1986-04-01 1987-10-08 Boehringer Ingelheim Kg PELLET SHAPES
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
CA1290526C (en) * 1986-11-07 1991-10-15 Marianne Wieser Mold and die operation
DE3640574A1 (en) 1986-11-27 1988-06-09 Katjes Fassin Gmbh & Co Kg METHOD FOR PRODUCING AN EDIBLE PRALINE-SHAPED PRODUCT AND DEVICE FOR IMPLEMENTING THE METHOD
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4813818A (en) * 1987-08-25 1989-03-21 Michael Sanzone Apparatus and method for feeding powdered materials
DE3822095A1 (en) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab NEW MEDICAMENT FORMULATION AND METHOD FOR THE PRODUCTION THEREOF
DE3830353A1 (en) * 1988-09-07 1990-03-15 Basf Ag METHOD FOR THE CONTINUOUS PRODUCTION OF SOLID PHARMACEUTICAL FORMS
US4984240A (en) * 1988-12-22 1991-01-08 Codex Corporation Distributed switching architecture for communication module redundancy
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
FR2655266B1 (en) * 1989-12-05 1992-04-03 Smith Kline French Lab CIMETIDINE PHARMACEUTICAL COMPOSITIONS.
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
JP2801728B2 (en) * 1990-03-13 1998-09-21 フロイント産業株式会社 Sugar-coated product and method for producing the same
EP0461547A1 (en) 1990-06-15 1991-12-18 Swatch Ag Watch with time zone display elements fitted to the bracelet thereof and set of such elements to be mounted on such a watch
US5538125A (en) * 1990-11-05 1996-07-23 Mcneil-Ppc, Inc. Indexing and feeding systems for apparatus for gelatin coating tablets
US5503673A (en) * 1990-11-05 1996-04-02 Mcneil-Ppc, Inc Apparatus for dip coating product
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5579338A (en) * 1992-06-29 1996-11-26 Mitsubishi Denki Kabushiki Kaisha Spread spectrum receiver using partial correlations
IT1255522B (en) 1992-09-24 1995-11-09 Ubaldo Conte COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS
JPH07507564A (en) 1992-09-30 1995-08-24 ファイザー・インク. Articles containing a core and a coating of variable thickness
JP2524955B2 (en) * 1993-04-22 1996-08-14 トーワ株式会社 Method and apparatus for resin sealing molding of electronic parts
ZA944949B (en) 1993-07-12 1995-04-05 Smithkline Beecham Corp Matrix-entrapped beadlet preparation
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
DE4446468A1 (en) * 1994-12-23 1996-06-27 Basf Ag Process for the production of coated tablets
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US6185356B1 (en) 1995-06-27 2001-02-06 Lumitex, Inc. Protective cover for a lighting device
GB9517031D0 (en) 1995-08-19 1995-10-25 Procter & Gamble Confection compositions
DE19539361A1 (en) 1995-10-23 1997-04-24 Basf Ag Process for the preparation of multilayer, solid pharmaceutical forms for oral or rectal administration
IT1282576B1 (en) * 1996-02-06 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET SUITABLE TO GIVE THE ACTIVE SUBSTANCE IN SUBSEQUENT AND PREDETERMINABLE TIMES
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5837301A (en) * 1997-04-28 1998-11-17 Husky Injection Molding Systems Ltd. Injection molding machine having a high speed turret
DE59812488D1 (en) 1997-07-09 2005-02-17 Swiss Caps Rechte & Lizenzen METHOD AND DEVICE FOR PRODUCING A MULTILAYER, PHYSIOLOGICALLY COMPATIBLE PHARMACEUTICAL FORM
US5942034A (en) * 1997-07-24 1999-08-24 Bayer Corporation Apparatus for the gelatin coating of medicaments
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6365183B1 (en) 1998-05-07 2002-04-02 Alza Corporation Method of fabricating a banded prolonged release active agent dosage form
US6544554B1 (en) 1998-05-15 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Regulated release preparations
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
DE19941997A1 (en) 1999-09-02 2001-03-08 Gunther Meinhardt Voss Method and device for producing a tablet or the like
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US6982094B2 (en) * 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US6742646B2 (en) * 2001-09-28 2004-06-01 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US20030066068A1 (en) * 2001-09-28 2003-04-03 Koninklijke Philips Electronics N.V. Individual recommender database using profiles of others

Patent Citations (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86973A (en) * 1869-02-16 Improvement in tarn-guide and clearer
US124183A (en) * 1872-02-27 Improvement in packings for engines
US2307371A (en) * 1941-08-13 1943-01-05 Ray O Vac Co Molding process
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3146169A (en) * 1960-01-21 1964-08-25 Burroughs Wellcome Co Pharmaceutical formulations and their manufacture
US3085942A (en) * 1960-12-28 1963-04-16 Hoffmann La Roche Antitussive compositions and preparation
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
US3726622A (en) * 1971-08-20 1973-04-10 Wolverine Pentronix Compacting apparatus
US4139589A (en) * 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US4230693A (en) * 1975-04-21 1980-10-28 Armour-Dial, Inc. Antacid tablets and processes for their preparation
US4097606A (en) * 1975-10-08 1978-06-27 Bristol-Myers Company APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same
US4371516A (en) * 1976-10-06 1983-02-01 John Wyeth & Brother Limited Articles for carrying chemicals
US4139627A (en) * 1977-10-06 1979-02-13 Beecham Inc. Anesthetic lozenges
US4425332A (en) * 1978-09-21 1984-01-10 Beecham Group Limited Antacid composition
US4273793A (en) * 1979-10-26 1981-06-16 General Foods Corporation Apparatus and process for the preparation of gasified confectionaries by pressurized injection molding
US4271206A (en) * 1979-10-26 1981-06-02 General Foods Corporation Gasified candy having a predetermined shape
US4362757A (en) * 1980-10-22 1982-12-07 Amstar Corporation Crystallized, readily water dispersible sugar product containing heat sensitive, acidic or high invert sugar substances
US5002970A (en) * 1981-07-31 1991-03-26 Eby Iii George A Flavor masked ionizable zinc compositions for oral absorption
US4372942A (en) * 1981-08-13 1983-02-08 Beecham Inc. Candy base and liquid center hard candy made therefrom
US4517205A (en) * 1983-01-03 1985-05-14 Nabisco Brands, Inc. Co-deposited two-component hard candy
US4882167A (en) * 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4781714A (en) * 1983-11-02 1988-11-01 Alza Corporation Dispenser for delivering thermo-responsive composition
US4661521A (en) * 1984-04-30 1987-04-28 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4686212A (en) * 1985-08-13 1987-08-11 Pharmacontrol Corp. Stable sodium aspirin tablet compositions
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US5229164A (en) * 1985-12-19 1993-07-20 Capsoid Pharma Gmbh Process for producing individually dosed administration forms
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4762719A (en) * 1986-08-07 1988-08-09 Mark Forester Powder filled cough product
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4894236A (en) * 1988-01-12 1990-01-16 Choong-Gook Jang Direct compression tablet binders for acetaminophen
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5459983A (en) * 1989-09-20 1995-10-24 Banner Gelatin Products Corp. Tablet enrobing apparatus
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5213808A (en) * 1989-09-22 1993-05-25 Buhk Meditec A/A Controlled release article with pulsatile release
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5368863A (en) * 1990-01-24 1994-11-29 Alza Corporation Long-term delivery device with early startup
US4980169A (en) * 1990-05-03 1990-12-25 Warner-Lambert Company Flavor enhancing and increasing efficacy of cough drops
US4983394A (en) * 1990-05-03 1991-01-08 Warner-Lambert Company Flavor enhancing and medicinal taste masking agent
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5464631A (en) * 1990-06-27 1995-11-07 Warner-Lambert Company Encapsulated dosage forms
US5228916A (en) * 1990-11-05 1993-07-20 Mcneil-Ppc, Inc. Apparatus for creating a gelatin coating
US5436026A (en) * 1990-11-05 1995-07-25 Mcneil-Ppc, Inc. Discharge and transfer system for apparatus for gelatin coating tablets
US5405642A (en) * 1991-02-27 1995-04-11 Janssen Pharmaceutica N.V. Method of highlighting intagliations in tablets
US5489436A (en) * 1991-06-14 1996-02-06 Mcneil-Ppc, Inc. Taste mask coatings for preparation of chewable pharmaceutical tablets
US5200191A (en) * 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
US5830501A (en) * 1991-12-06 1998-11-03 Alza Corporation Dosage form comprising hydrophilic polymer
US5511361A (en) * 1992-08-07 1996-04-30 Warner-Lambert Company Encapsulation method
US5795588A (en) * 1992-08-07 1998-08-18 Warner-Lambert Company Encapsulated product
US5609010A (en) * 1992-08-07 1997-03-11 Warner-Lambert Company Encapsulation method
US5456920A (en) * 1993-02-10 1995-10-10 Takeda Chemical Industries, Ltd. Uncoated tablets and method of producing the same
US5391378A (en) * 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
US5681584A (en) * 1993-04-23 1997-10-28 Ciba-Geigy Corporation Controlled release drug delivery device
US5415868A (en) * 1993-06-09 1995-05-16 L. Perrigo Company Caplets with gelatin cover and process for making same
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US5853760A (en) * 1993-12-04 1998-12-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Device for the controlled release of active substances
US5711961A (en) * 1994-07-26 1998-01-27 Apr Applied Pharma Research S.A. Pharmaceutical compositions based on chewing gum and a method for the preparation thereof
US5830502A (en) * 1994-10-28 1998-11-03 Alza Corporation Injection-molded dosage form
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US6117479A (en) * 1995-05-09 2000-09-12 Phoqus Limited Electrostatic coating
US5578336A (en) * 1995-06-07 1996-11-26 Monte; Woodrow C. Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making
US5614207A (en) * 1995-06-30 1997-03-25 Mcneil-Ppc, Inc. Dry mouth lozenge
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
US5824338A (en) * 1996-08-19 1998-10-20 L. Perrigo Company Caplet and gelatin covering therefor
US6001391A (en) * 1997-03-12 1999-12-14 Basf Aktiengesellschaft Process for producing solid drug forms having at least two phases
US6149939A (en) * 1997-05-09 2000-11-21 Strumor; Mathew A. Healthful dissolvable oral tablets, and mini-bars
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6103257A (en) * 1998-07-17 2000-08-15 Num-Pop, Inc. System for delivering pharmaceuticals to the buccal mucosa
US6200590B1 (en) * 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US6350398B1 (en) * 1998-09-03 2002-02-26 Basf Aktiengesellschaft Process for producing coated solid dosage forms
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US6149943A (en) * 1998-09-04 2000-11-21 Mcneil-Ppc, Inc. Microcrystalline cellulose particles having active core
US20010001280A1 (en) * 1998-09-09 2001-05-17 Liang-Chang Dong Dosage form comprising liquid formulation
US6248361B1 (en) * 1999-02-26 2001-06-19 Integ, Ltd. Water-soluble folic acid compositions
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237855A1 (en) * 2006-04-05 2007-10-11 Cadbury Adams Usa Llc Calcium phosphate complex in acid containing confectionery
US20100297203A1 (en) * 2006-04-05 2010-11-25 Cadbury Adams Usa, Llc Impact of calcium phosphate complex on dental caries
US8133476B2 (en) 2006-04-05 2012-03-13 Cadbury Adams Usa Llc Calcium phosphate complex and salts in oral delivery systems
US8252269B2 (en) 2006-04-05 2012-08-28 Cadbury Adams Usa, Llc Impact of calcium phosphate complex on dental caries
US20090018639A1 (en) * 2007-07-11 2009-01-15 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20100255084A1 (en) * 2009-04-06 2010-10-07 Yoel Ovil Medicinal melting capsules for oral mucosal absorption
US20100255088A1 (en) * 2009-04-06 2010-10-07 Yoel Ovil Method for delivering a combination of resveratrol and aspirin for use in treatment and prevention of vascular disease
US20100255086A1 (en) * 2009-04-06 2010-10-07 Yoel Ovil Method for oral mucosal absorption of acetyl salycylic acid
WO2018217241A1 (en) 2017-05-22 2018-11-29 Johnson & Johnson Consumer Inc. Lozenge dosage form
US10500155B2 (en) 2017-05-22 2019-12-10 Johnson & Johnson Consumer Inc. Lozenge dosage form having a disintegrative tablet portion and a candy glass shell portion

Also Published As

Publication number Publication date
ZA200403166B (en) 2005-05-18
CA2462008C (en) 2010-08-31
KR20040039458A (en) 2004-05-10
NO20041716L (en) 2004-04-27
ES2319971T3 (en) 2009-05-18
PL369169A1 (en) 2005-04-18
US6837696B2 (en) 2005-01-04
WO2003028990A1 (en) 2003-04-10
US20030068367A1 (en) 2003-04-10
AU2002337711B2 (en) 2008-06-05
US20090186082A1 (en) 2009-07-23
CN1578724A (en) 2005-02-09
ZA200403167B (en) 2005-05-27
NZ532095A (en) 2005-12-23
EP1429915B1 (en) 2009-01-14
CN100488763C (en) 2009-05-20
EP1429915A1 (en) 2004-06-23
KR100861670B1 (en) 2008-10-07
DE60230886D1 (en) 2009-03-05
ATE420762T1 (en) 2009-01-15
JP2005504639A (en) 2005-02-17
CA2462008A1 (en) 2003-04-10
MXPA04002971A (en) 2005-06-20
CN1946378A (en) 2007-04-11
HUP0401653A2 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
EP1429724B1 (en) Dosage form containing a confectionery composition
US20050019376A1 (en) Dosage form containing a confectionery composition
US20040146559A1 (en) Dosage forms having an inner core and outer shell with different shapes
US20070190133A1 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
EP1811968B1 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
US20210378968A1 (en) Multi-cavity customizable dosage forms
US20060088587A1 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
US20230149443A1 (en) Customizable dosage forms containing simethicone
AU2002337783A1 (en) Dosage forms having an inner core and outer shell with different shapes
AU2002334735A1 (en) Dosage forms having an inner core and outer shell

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCNEIL-PPC, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCNALLY, GERARD P.;BUNICK, FRANK J.;SOWDEN, HARRY S.;AND OTHERS;REEL/FRAME:015323/0945;SIGNING DATES FROM 20040414 TO 20040511

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION